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ABSTRACT
GENE REGULATION THROUGH ARTIFICIALLY INDUCED DNA
CONFORMATIONAL CHANGES

By
David Bednarski
May 2008

Thesis supervised by Steven Firestine, Ph. D.
The conformation of DNA has been shown to play an important role in the
regulation of gene expression. A consequence of this finding is that agents that alter the
conformation of DNA should also affect the regulation of gene expression. To explore
this, we used tethered-triple helix oligonucleotides (TFO) to bend DNA. We show that
the expression of a luciferase gene is regulated by the presence of an induced DNA bend.
Bends occurring in the same orientation as RNA polymerase binding result in a 93%
increase in expression. In contrast, bends induced in that opposite direction resulted in a
51% decrease in expression. These results prompted us to investigate the synthesis of
three small molecules with the potential to induce a sequence selective bend in DNA.
These studies revealed that the compounds were able to induce a DNA bend counter to an
intrinsic bend present in a target DNA fragment.
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I. LITERATURE SURVEY
Gene expression is a fundamental biological process in which DNA sequences are
converted to RNA and proteins crucial to the life of an organism. Cells regulate gene
expression to control a multitude of functions from normal cell maintenance to apoptosis.
Gene expression can be regulated at any step of the process, from transcription to protein
modification. Aberrant gene expression is the result of a loss of normal regulation and is
linked to a number of diseases ranging from cancer to Alzheimer’s disease.1-5 The
development of new mechanisms of artificial gene regulation will lead to the creation of
pharmacological agents capable of treating a variety of diseases.
A number of methods have been employed to establish artificial control over gene
expression. These methods have utilized a wide range of ligands, from DNA to proteins
and small molecules.6-64 These methods seek to either inhibit or recruit the binding of
proteins to DNA or mRNA to alter the expression of a target gene. An under utilized
method to establish artificial gene regulation is to alter the conformation of DNA,
particularly upstream of a target gene. The flexibility of DNA and the conformations that
it can adopt, particularly DNA bends, play important roles in various processes including
transcription. Though DNA can be intrinsically bent and can be bent by the binding of
various proteins, these methods are not acceptable pharmacological treatment methods.
Such treatment methods require the bending of DNA through artificial means, including
nucleic acids and small molecules.
I.A. Artificial Gene Regulation
There are a number of mechanisms that have been used to establish artificial
control over gene expression including antisense oligonucleotides, RNAi, zinc finger
1

proteins, triple helix oligonucleotides, peptide nucleic acids, and small molecules. These
methods will be individually discussed below.

Antisense Oligonucleotides
Gene expression has been modified through targeting mRNA with the intent of
either blocking its translation or degrading it through enzymatic action, silencing the
expression of its parent gene. A number of oligonucleotides have been used to form
duplexes with target mRNA to inhibit the translation of the mRNA and silence the
expression of a gene. These complementary oligonucleotides have included DNA, the
oligonucleotide analogue PNA, LNA and PMO.6-10 DNA and PNA will be discussed in
greater depth (see Triple Helix Oligonucleotides and Peptide Nucleic Acids sections).
LNA, locked nucleic acid, are oligonucleotide analogues of RNA. The bases of
LNA contain methylene linkages between the 2’ oxygen and the 4’ carbon of the ribose
ring. This linkage locks the 3’-carbon in the endo conformation, resulting in high-affinity
binding and increased melting temperature.6-7 LNA complementary to target mRNA is
able to form duplexes that activate RNase H, resulting in the degradation of mRNA and
the silencing of the expression of a target gene.
PMOs or phosphorodiamidate morpholino oligonucleotides are oligonucleotide
analogues that display the standard nucleic acid bases. The deoxyribose rings of DNA
and the ribose rings of RNA are replaced with six-membered morpholine rings while the
phosphate linkers were replaced with phosphorodiamidate groups. The inclusion of the
phosphorodiamidate groups eliminated the negative charge of the phosphate backbone
under physiological conditions allowing PMOs to bind to their RNA targets without the
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negative charge repulsion present in the formation of DNA/RNA and dsRNA duplexes.
PMOs were targeted to 25-bp regions of mRNA to block the binding of the ribosomal
intitiation complex, inhibiting the translation of mRNA.8-9

In addition, PMOs can

interfere with the splicing of introns from pre-processed mRNA to alter the expression of
a gene.8,10-11

RNA Interference
Genes have been down regulated and completely silenced by interfering with the
translation of mRNA through the formation of double-stranded RNA using a technique
called RNA interference, RNAi.12

RNAi methods are derived from the native

degradation of RNA through the formation of double stranded RNA. These methods
redirect this process to target the mRNA of a gene of interest.12-13 Double-stranded RNA,
homologous to a target sequence of mRNA, is delivered to the nucleus of a cell (Fig. 1).
Riobnuclease III cleaves these dsRNA strands into 21- and 22-nucleotide fragments
called small interfering RNA, siRNA. The generated siRNA bind to the target mRNA
strands and create new RNA duplexes. Like the dsRNA parent of the siRNA fragments,
the mRNA/siRNA duplexes are degraded by a protein complex called Dicer, silencing
the expression of the originating gene. This method has been used to silence reporter
genes in Drosophila and mammalian cell lines.12 RNAi was also used to produce highamylose potatoes by silencing two genes encoding for starch branching enzymes.13
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ribonuclease III

nucleus

cytoplasm

dsRNA

dsRNA

Dicer

mRNA

siRNA

siRNA/mRNA

RNA
fragment

nuclear membrane
cell membrane

Figure 1. RNA interference occurs when dsRNA enters the nucleus of and is broken
down into 21- and 22-nucleotide siRNA by ribonuclease III. siRNA then bind to target
mRNA creating siRNA/mRNA duplexes that are cleaved into small fragments by
ribonuclease III, preventing translation of the mRNA.

Zinc Finger Proteins
Protein-based systems have also been used to activate transcription.

These

activation systems were composed of two main domains, a DNA binding domain
responsible for binding to a specific DNA sequence and an activation domain that
recruites a transcriptional complex. These systems included both fusion proteins and
independent proteins that activate transcription upon dimerization. A system composed
of DNA-binding domain proteins and activation domain proteins was used to activate
transcription, both in vitro and in vivo, upon dimerization by a dimerization ligand.14 The
proteins that have been used for targeting DNA sequences and for activating transcription
are highly variable, though one of the most commonly used protein-based DNA-binding
domains were zinc finger-proteins.15-16
Zinc finger-proteins are composed of C2H2ZF domains, an α-helix packed against
two anti-parallel β-strands with stability provided by the coordination of a zinc ion by the
side chains of two cysteine and two histidine residues (Fig. 2). Zinc finger proteins are
able to bind to a variety of DNA sequences due to the variability of the DNA binding
4

region of the proteins. The N-terminus residues of the zinc finger domain α-helix make
contact with the major groove of DNA at a recognition triplet, which is customizable
based on the amino acids of the particular domain.15-16

Unfortunately, zinc finger

proteins cannot target all DNA sequences with equal efficiency; the zinc finger domain
has difficulty targeting pyrimidines; cytosine and thymine.

Figure 2. Polydactyl zinc fingers bound to DNA. The zinc fingers are blue, the DNA is
orange and the zinc ions are green. Zinc ions are coordinated by two cysteine and two
histidine residues. Figure from PDB 1A1L, ZIF268 zinc finger-DNA complex (GCAC
SITE).17
Multiple zinc fingers domains have been linked to form polydactyl zinc finger
proteins to target longer, more specific DNA targets (Fig. 2). Polydactyl zinc fingerproteins have been used as DNA-binding domains for a number of gene activation motifs
with activation domain proteins such as TBP and variations of the herpes simplex virus
VP16 activation domain.18-19 These fusion proteins were used to activate the expression

5

of oncogenic genes ErbB-2 and ErbB-3, angiogenic genes VEGF-A and CD144,
apoptotic gene BAX, and γ-globin as a potential treatment for sickle cell anemia.15-16,20-21
When conjugated to KRAB (Krüppel associated box), ERD, ERF repressor domain, or
SID (mSIN3 interaction domain), zinc finger-proteins served as binding partners for
repressor domains.19

Triple Helix Oligonucleotides
TFOs are single strands of DNA that are able to bind in the major groove of DNA
through hydrogen bonds with the purine members of DNA base pairs, though they can
tolerate some pyrimidines in their binding region. There are two modes for this hydrogen
bonding to occur, parallel and antiparallel, dependent on the orientation of a TFO in the
major groove.22-24 The purine-rich DNA strand serves as a reference when determining
the binding mode of the TFO. Parallel binding occurs when the TFO and a purine-rich
DNA strand are in parallel, aligned with their 5’ and 3’ ends in the same orientation. The
hydrogen bonding that occurs in the parallel binding orientation is called Hoogsteen base
pairing, or the pyrimidine motif (Fig. 3A). TFO thymines bind to duplex adenines, while
protonated cytosines of TFOs bind to duplex guanines. Due to TFO cytosines requiring
protonation to bind, triplex formation in parallel systems is pH dependent, favoring acidic
environments.
The other TFO binding motif that a TFO can bind into duplex DNA is one with an
antiparallel orientation. A TFO and a purine-rich DNA strand of a DNA duplex run
opposite of one another in terms of 5’-3’ directionality. The hydrogen bonds formed
between TFOs and antiparallel DNA are known as Reverse Hoogsteen or the purine
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motif (Fig. 3B). Reverse Hoogsteen base pairing is comprised of purines hydrogen
bonding to purines; adenine binds to adenine and guanine binds to guanine.

The

antiparallel orientation can also contain thymines of a TFO strand bound to the adenines
of the purine-rich duplex DNA strand.25 Unlike regular Hoogsteen base pairing, Reverse
Hoogsteen bonds do not have a pH requirement.
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Figure 3. (A) Hoogsteen base pairs used in the formation of DNA triplexes; thymine to a
Watson-Crick base paired adenine and thymine and a protonated cytosine to a WatsonCrick base paired guanine and cytosine. (B) The Reverse Hoogsteen hydrogen bonding
motif found in triplex DNA.
Single TFOs have been used to both inhibit and activate transcription. TFOs have
been used as antigene inhibitors that bind to target DNA sequences to inhibit gene
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expression, most often blocking transcriptional initiation.26 The expression of c-myc
genes, rat α1(I) genes and oncogenic Ets2 genes were inhibited by binding TFOs to their
respective promoters.27-30

TFOs have been used to block specific DNA-protein

interactions integral to transcriptional activation. TFOs inhibited gene expression when
bound to the binding sites of Sp1 and SPy transcriptional factors in the promoter regions
of Ha-ras and c-Src genes.31-32 In addition to preventing transcriptional activation, TFOs
were used to inhibit transcriptional elongation by arresting the progression of bacterial
RNA polymerase in in vitro experiments through the binding of TFOs to sites within a
gene sequence.33
Transcription was also inhibited by TFOs that mediated genomic modifications.
DNA-damaging agents, such as psoralen, were coupled to TFOs to achieve site-directed
DNA damage.34 Psoralens intercalated cellular DNA to form monoadducts and double
strand crosslinks upon activation by UV irradiation.35-36 TFO/psoralen conjugates have
been used to selectively inactivate transcription in skin cells as a treatment for psorosis.35
Duplex DNA was distorted upon formation of either monoadducts or crosslinks by
psoralen.

These distortions are recognized and repaired by nuclear excision repair

mechanisms that leads to strand breaks and recombination that eliminated and activated
gene expression.36-37
TFOs also activated transcription by acting as the DNA-binding domain for
protein and oligonucleotide activation domains. TFOs were conjugated to hairpin DNA
that contained transcription factor binding sites.38 Transcriptional machinery will be
recruited to the TFO/hairpin-DNA conjugate, when bound to DNA, initiating
transcription.

8

As guanine-rich oligonucleotides, TFO were prone to self-association into
quartets and tetrads in physiological concentrations of potassium.34 TFOs were also
limited by negative charge repulsion between the phosphate backbones of the duplex
DNA and the TFO. Replacement of three or four adjacent 2’-O-methyl sugars of the
TFO backbone with 2’-O-aminoethyl riboses alleviates this repulsion and stabilizes the
triplex.39

Peptide Nucleic Acids
PNAs are oligonucleotide analogues in which the sugar phosphate group is
replaced with a uncharged N-(2-aminoethyl)glycine unit (Fig. 4A).40-42 Peptide nucleic
acids have also been used to artificially regulate gene expression. Unlike TFOs, PNAs
were not limited by negative charge repulsion with the backbones of target DNA. PNAs
are uncharged under physiological conditions and are resistant to nucleases and proteases,
making them a more stable alternative to TFOs for targeting transcription to alter
transcription.
PNA binds to DNA by forming both Watson-Crick and Hoogsteen base pairs.
PNAs can bind to dsDNA by displacing the second strand of DNA (Fig. 4B). A second
strand of PNA can bind to a PNA/DNA duplex to form a triplex. The displaced DNA
strand forms a single-stranded displacement loop (D-loop) recognized by RNA
polymerase as an initiation site comparable to a strong promoter.43 PNAs have been
targeted to sites where transcriptional activation was desired, such as upstream of γglobin genes to treat sickle cell anemia.40
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Figure 4. (A) PNA backbone consisting of uncharged N-(2-aminoethyl)glycine units
linked by amide bonds. (B) PNA binds to DNA forming triplexes that displace one
strand of DNA forming a D-loop.
Additionally, PNAs have been used to inhibit transcription. PNAs were used in
an antigene mechanism by binding to the ssDNA of open transcription complexes in
chromosomal DNA, arresting transcription by inhibiting elongation.44 Antigene PNA
was used to down regulate the mutant KRAS gene, with minimal effect to wild-type
KRAS.41 Like TFOs, PNA has been used to block the binding sites of proteins required
for gene activation.42 PNAs were also used to deliver DNA damaging agents, such as
psoralen, to a particular sequence to induce DNA repair and silence a gene.36
While lacking the negative charge repulsion limitation of TFOs and other
oligonucleotides, PNAs are limited in their ability to penetrate cell membranes.
However, conjugations of PNA with cell penetrating peptides and nuclear localization
10

peptides have been shown to ease the passage of PNA through cell and nuclear
membranes.41,45

Small Molecules
There are a number of small molecules that have been used to control gene
expression by targeting transcription by targeting transcriptional factors and DNA to
inhibit or activate transcription. These will be discussed below.
Small molecules have been used to inhibit transcription by targeting transcription
factors. An example of small molecules that functioned in this capacity was β-peptide
peptidomimetics. These peptide backbone analogues inhibited the interaction between
p53 and hMD2.46-47 The hMD2 protein negatively regulates p53, a tumor suppressor
transcription factor. β-peptide mimics of p53 bound to hMD2, allowing p53 to activate
the transcription of genes that suppressed tumor growth and genes that promoted cell
cycle arrest and apoptosis. Similarly, small molecules were used to inhibit the interaction
of p53 with MDM2, which is overexpressed in tumor cells and inhibited the activity of
p53 to suppress tumor growth.47
Small molecules can also target DNA to affect transcription and artificially
regulate gene expression. Most compounds that target DNA bind to the minor groove
and display a preference for AT-rich DNA sequences. This selectivity is largely due to
the steric hindrance presented by the exocyclic amine of the guanine nucleotide in the
minor groove. Polyamides netropsin and distamycin (Fig. 5) are naturally occurring
antibiotics that served as the parent compounds of a series of sequence selective minor
groove binding agents. Netropsin and distamycin displayed a preference for binding to
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AT-rich regions of DNA. The binding energy of these compounds is derived from
hydrogen bonds formed between the amide-NH groups of the compounds and the
hydrogen bond acceptors in the minor groove. Additional binding energy was provided
by electrostatic interactions between the positively-charged amindine tails of the
compounds and the negatively-charged phosphate oxygens of the DNA backbone.
Binding affinity is also enhanced by the hydrophobic interactions between the aromatic
rings of the compound and the carbons of the ribose ring of DNA.
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Figure 5. Polyamides netropsin and distamycin.
Polyamides, represented by distamycin, were able to bind to the DNA minor
groove in two different binding modes based upon the stoichiometry of binding either 1:1
or 2:1. The first binding mode, 1:1, consisted of a single distamycin molecule bound in
the minor groove of an AT-rich region of DNA (Fig. 6A). The 1:1 binding motif is the
predominant binding mode at lower concentrations of the antibiotic. Distamycin can
bind in either orientation (Fig. 6A).48
At higher concentrations of distamycin the second binding mode, 2:1, becomes
the prevalent binding motif.49 The 2:1 binding mode involved two distamycin molecules
binding to the same AT-rich DNA minor groove site (Fig. 6B). The minor groove is
widened to accommodate the binding of two molecules.

The binding of the first
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distamycin lowers the binding energy for the second distamycin and increases the second
distamycin’s rate of binding.50 The 2:1 binding mode is stabilized by dipole-dipole
interactions between the pyrrole rings and the amide bonds of the molecules. In this
binding mode each distamycin is bound to a single strand of DNA, preventing bifurcated
hydrogen bonds, which in turn increased the selectivity of the duplex toward AT-rich
sequences in the minor groove.

A

B

Figure 6. Two binding modes seen in NMR studies of distamycin-DNA binding. The
(A) 1:1 binding mode and (B) 2:1 binding mode, distamycin to DNA. There are two
orientations possible for the 2:1 binding mode, parallel and anti-parallel, both of which
result in a widening of the minor groove. Parallel binding has not been experimentally
observed.

13

The 2:1 binding mode could occur in two different orientations; parallel and antiparallel (Fig. 6B). The parallel orientation involved the stacking of two distamycin
molecules such that their positively-charged amidine tails lay in the same direction. Due
to charge-charge repulsion of the amidine tails, parallel 2:1 binding does not occur. The
anti-parallel 2:1 binding mode, however, has been experimentally observed and is the
most common higher order structure formed. In the antiparallel binding mode, the
distamycin molecules were stacked with their positively-charged tails at opposite ends of
the binding motif, such that there is no charge-charge interaction between them.
The 2:1 binding mode of distamycin allows both strands of a DNA sequence to be
targeted in the minor groove in a sequence selective manner. Dervan used distamycin as
a lead compound in the creation of sequence selective minor groove binding
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Figure 7. (A) Example of Dervan’s hairpin polyamide.52 (B) Hairpin polyamide from A
bound to the minor groove of the DNA. DNA is shown from a perspective of looking at
the base pairs from their edge, with circled H’s representing hydrogen bond donors while
circles with two dots, lone pair electrons, represent hydrogen bond acceptors.52
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polyamides.51 Dervan’s polyamide minor groove binders utilized various heterocycles
linked by amide bonds. These polyamides, called lexitropsins, bound to DNA in the antiparallel 2:1 binding mode. Two lexitropsin molecules were then linked at one end with
an aliphatic amino acid to create a hairpin polyamide (Fig. 7A). The side-by-side binding
of these polyamide chains, with each chain targeting one strand of DNA, allowed this
system to target all four base pair arrangements in any sequence (Fig. 7B).
The hairpin polyamide system utilized three different heterocyclic systems to
recognize DNA; pyrrole (Py), imidazole (Im) and hydroxypyrrole (Hp) (Fig. 8). The Nmethylpyrroles of the lead compound, distamycin, could target the N3 of adenine and the
O2 of thymine in a bifurcated fashion with the connecting amide-NH groups. In the 2:1
binding motif, where only a single strand of DNA would be targeted by the moiety, either
adenine or thymine could be targeted by an N-methylpyrrole (Fig. 8). N-methylpyrroles
could also accommodate the O2 of cytosine, normally inaccessible in the 1:1 binding
motif due to steric hindrance of the exocyclic amine of guanine in the minor groove.
Hairpin polyamides could therefore use N-methylpyrroles to target adenine, thymine or
cytosine nucleotides.
Recognition of guanine presented a problem due to the protrusion of the exocyclic
amine group into the minor groove.

Guanine targeting was accomplished by the

incorporation of imidazoles (Im) into the molecule. Imidazoles act as hydrogen bond
acceptors to the exocyclic (Fig. 8B). The ability to target guanine allowed for the
creation of hairpin polyamides capable of distinguishing between GC and CG base pairs
with a combination of pyrrole and imidazole; Im/Py could target GC, while Py/Im could
target CG base pairs.
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Figure 8. Minor groove binding schemes of heterocycles used in Dervan’s polyamides
in AT and GC base pairs; (A) pyrrole, Py, (B) imidazole, Im, and (C) 3-hydroxypyrrole,
Hp.
Dervan’s hairpin polyamides also possessed the ability to distinguish between AT
and TA base pairs. While paired pyrroles could target both adenine and thymine, there
was no distinction between AT and TA. By pairing an N-methylpyrrole with a 3hydroxypyrrole (Hp) in a hairpin polyamide AT and TA could be differentiated and
independently targeted. N-methylpyrroles cause a shift in the hydrogen bonding scheme
of a polyamide depending on whether the N3 of an adenine or the O2 of a thymine is
targeted.

3-Hydroxypyrrole alleviated this shifting by displaying a preference for

thymine due to the presence of the hydroxy group.53-54 This hydroxy group also may
hydrogen bond with the O2 of thymine (Fig. 8C).54 Combinations of N-methylpyrrole
and 3-hydroxypyrrole in hairpin polyamides allowed for the independent targeting of AT
and TA base pairs, Py/Hp and Hp/Py, respectively.
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Hairpin polyamides are able to target AT, TA, GC and CG base pairs
independently (Table I). This allowed molecules to be created to specifically target any
sequence in DNA. In addition to N-methylpyrrole, 3-hydroxpyrrole and imidazole a
number of other heterocycles have been placed into polyamide chains including thiazoles,
furans, oxazoles and benzimidazoles, among many others.54-55

Table I: The sequence recognition of hairpin polyamides by heterocylic pair, where “+”
indicates recognition and “–” indicates no recognition.
Pair

AT

TA

GC

CG

Py/Hp

+

-

-

-

Hp/Py

-

+

-

-

Im/Py

-

-

+

-

Py/Im

-

-

-

+

Polyamides are the only class of small molecules capable of selectively targeting
any predetermined DNA sequence and have been used to both inhibit and activate
transcription in a sequence-specific manner.56

Polyamides were used to block the

binding sites of transcription factors to inhibit the expression of adjacent genes by
preventing crucial protein-DNA interactions.56-60 Polyamides were used in this fashion to
block the binding of TFIIIA to inhibit the expression of the 5S ribosomal gene in vitro.5758

Gene expression was inhibited in other instances where polyamides were used to block

the binding sites of transcription factors such as LEF-1, Ets-1.56 The transcription of
other genes, bHLH and hTGF- β1, were inhibited by binding polyamides in the respective
promoter regions.56,59 Polyamides were also bound to the hypoxia response element to
prevent the binding of hypoxia-induced factor to reduce the expression of VEGF.60
The customizability of polyamides to target any sequence of DNA permitted
polyamides to serve as the DNA-binding domains of dual-domain transcriptional
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activators.56,61-62 The activation domains of these activator complexes included both
peptide ligands and other small molecules. Hairpin polyamides tethered to activating
peptides derived from the herpes simplex virus VP16 activator, were used to stimulate
promoter specific transcription.62
Peptide-based activation domains were replaced with small molecules to create
completely synthetic small molecule transcriptional activators.63-64 Hairpin polyamides
fused to isoxazolidines mimics of activation domains, were used as artificial transcription
factors (Fig. 9).63 Fusions of hairpin polyamides to a molecule called wrenchnolol
initiated transcription in a sequence-specific manner.64
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Figure 9. The structures of (A) isoxazolidines and (B) wrenchnolol.

I.B. DNA Bending
One method which has not received much attention in the artificial regulation of
gene expression is the role that DNA conformation plays in gene regulation.

The

common structural perception of DNA is that it exists as a rigid, rod-like, double helix.
DNA, however, is not a rigid molecule. DNA possesses a level of flexibility critical to
numerous cellular activities.

The flexibility of DNA is derived from the potential
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deformability of its structure, specifically the structures and interactions of the nucleotide
bases (Fig. 10).65-67 This flexibility is best described in terms of “inverse stiffness” and is
expressed as a persistence length, the distance over which DNA is effectively linear.68-70
The persistence length is dependent on both the rigidity of DNA and sequence-derived,
intrinsic DNA curvature. DNA fragments shorter than 150 base pairs are considered to
have rigid, linear character, while DNA sequences longer than 150 base pairs possessed
more flexibility and have slightly curved structures.69 The flexibility of DNA allow for
protein interactions necessary for the various activities of DNA, ranging from packaging
in nucleosomes to transcription.
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Figure 10. Watson-Crick base pairs; adenine, A, to thymine, T, and guanine, G, to
cytosine, C.
The innate flexibility of DNA allows it to adopt various conformations, distorting
it from the aforementioned rod-like structure. These conformations range from simple
bends to full loops.71 These distortions are the result of the widening of one of the
grooves of a DNA region and compressing the complementary groove on the opposite
face of the double helix. These alterations in groove width are introduced into a DNA
sequence by one of two general mechanisms, either nucleotide sequence dependent
intrinsic bends or bends facilitated by an external force, such as a protein, cation or
drug.69,72-75
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Intrinsic conformation changes are the result of DNA sequences that possess a
higher level of flexibility than other sequences. The most common examples of these
sequences are AT-rich DNA sequences.73 These sequences are found throughout the
genome and interact with a variety of proteins including transcriptional proteins.76-77
Static bends of DNA are derived from steric interactions between base pairs of a
particular sequence. The best known example of an intrinsically bent DNA sequence is
the A-tract. A-tracts consist of a sequence of four to six adjacent adenine-thymine base
pairs that naturally bends the DNA toward the minor groove. The magnitude of the bend
is about 18° from linear DNA (as measured from the center of the helical axis) and is
caused by widening of the major groove as a result of a combination of tilt and roll
helical deformations between the adenine-thymine base pairs (Fig. 11).72,74,78-80 These Atracts are found within the genome and have roles in various DNA processes, including
replication and transcription, either by the curve that they possess or by serving as a
binding site for proteins that bind to pre-bent DNA.67,72,81-85

Figure 11. The helical parameters of DNA are influenced by the sequence of a region.
These are the basic helical deformations that can be caused by a base pair or between
base pairs as a result of steric interaction. Tilt (A) results in a change in the short axis
between base pairs, while a roll (B) results in a change along the long axis between two
base pairs. A twist (C) deformation results in adjacent base pairs twisting about the axis
of a DNA strand in relation to one another. A propeller twist (D) involves a twist within
a base pair, resulting in a less planar base pair and widening of the major groove. A
buckle (E) is a base pair deformation that also results in a less planar base pair; however
this change is due to a bend in the short axis between the nucleotides.
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While DNA conformation is affected by the sequence of nucleotides, DNA
conformation is also naturally altered by external forces, namely interactions with DNAbending proteins. These proteins included those that are architectural in nature serving
only to bend the DNA, and those which possess other major functions, in addition to
bending DNA. The methods by which these proteins bend DNA are varied, but can be
divided into two basic classes (Fig. 12); proteins that contact bent DNA on the convex
side of the bend, bending DNA away from their binding position, and proteins that
contact the concave side of DNA bends, bending the DNA around itself.69,75
The first class of DNA bending proteins, known as convex benders, bent DNA
through hydrophobic interactions between amino acids of the protein and base pairs in
the minor groove of the DNA. The presence of the amino acids in the minor groove, and
the resulting interactions, widened the minor groove, compressed the major groove and
bent the DNA away from the protein. A number of proteins functioned by this method
including transcriptional factors such as the eukaryotic TATA binding protein (TBP)
(Fig. 12).
The second class of DNA bending proteins, concave benders, functioned by
bending DNA toward or around themselves.

Many of these concave benders

electrostatically interact with the DNA.86 Examples of proteins that bend DNA from the
concave side of the bend included the eukaryotic histone octamer, the prokaryotic
integration host factor (IHF) and the prokaryotic catabolite-activating protein (CAP) (Fig.
12).
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Figure 12. Examples of DNA bending proteins. Protein that bends from the convex side
of the induced bend TBP, A. Proteins that bend DNA from the concave side of the
induced bend include nucleosome formation about a histone octamer, B; IHF, C; and
CAP, D.
I.C. DNA Bending and Transcription
I.C.1. Potential mechanisms for the role of DNA bending in transcription
The focus of this thesis is the crucial role DNA bending plays in transcriptional
regulation. Various studies have shown that DNA bending participates in transcription in
two main capacities. First, RNA polymerase causes DNA bending upon binding to the
promoter sequence of a gene. Second, the binding of transcription factors in the promoter
region of a gene also results in bent DNA, although it is possible that the binding sites of
some transcription factors are already pre-bent. Pre-bent DNA sequences may function
as a mechanism to attract the transcription factors to bind to their sites.67,85
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While it is generally agreed that DNA bending upstream in the promoter region of
a gene is important to the regulation of genetic expression, the mechanism of how
bending regulates gene expression remains in question.77,85 There are two basic theories
regarding the role played by DNA bends on gene regulation. The first theory suggests
that DNA bends function in an architectural capacity, bringing distally bound proteins
into proximity with the RNA polymerase (Fig. 13A), while the second theory suggests
that DNA bending facilitates DNA wrapping about RNA polymerase (Fig. 13B).

A

B

Figure 13. The two models of DNA bending and transcriptional regulation. (A)
Interactions between RNA polymerase and distally bound transcription factors brought
into proximity by DNA bend and (B) DNA wrapping facilitated by DNA bending.
The initiation of transcription requires the assembly of multiple protein
complexes. The proteins involved in these complexes may be bound at nonadjacent
DNA sites and must be brought into contact for the formation of the transcriptal initiation
complex.23,82-83,87-93 For example, transcription factors TFIIA, TFIIB, TFIIC, TFIID
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(also known as TBP), TFIIE, TFIIF and TFIIH and RNA polymerase in eukaryotic
systems all most interact to form the transcriptional complex. The control of expression
also involves interactions of the transcriptional complex and RNA polymerase with
proteins bound upstream such as activators, enhancers and repressors.

Interactions

between upstream and downstream proteins are facilitated through the distortion of the
intervening DNA helix, bringing the proteins of interest into proximity (Fig. 13A). In the
case of longer intervening DNA sequences, greater than 500 base pairs, the natural
flexibility of the DNA will allow bending to occur and the proteins will be brought into
the required proximity. However, for shorter distances, DNA is more rigid and requires
the binding of DNA-bending proteins to facilitate the formation of protein-protein
interactions necessary for the completion of the transcription initiation complex. Thus,
DNA bending regulates transcription by facilitating the interaction of RNA polymerase
and distally bound proteins.
The second theory regarding the role of upstream DNA bending and gene
regulation asserts that bending is required for wrapping DNA about RNA polymerase in
both prokaryotic and eukaryotic transcriptional complexes.83,94-96 DNA wrapping has
been visualized by footprinting, DNA supercoiling experiments, microscopy and proteinDNA crosslinking analysis.96 DNA becomes wrapped around RNA polymerase upon its
binding to the promoter region of a gene. RNA polymerase comes into contact with
DNA both upstream and downstream of the transcriptional start site (Fig. 13B). DNA
wrapping facilitates strand separation, required for transcription, by introducing torsional
strain in the double helix.
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Wrapping of DNA around RNA polymerase requires about 60 kJ/mol of energy to
alter the conformation of DNA.96 The presence of other DNA bending proteins, such as
TATA-binding protein (TBP) in eukaryotic transcription complexes, lessens the cost of
wrapping DNA around RNA polymerase.95,97 Upon binding, TBP induces an 80° bend
toward the major groove of DNA prior to RNA polymerase DNA wrapping. Pre-bent
DNA lowering the cost of DNA wrapping is also seen in prokaryotic systems, where
RNA polymerase binds to promoter regions that contain intrinsically bent DNA.83
While the exact role that DNA bends play in transcriptional regulation is
unknown, their position, subsequent directionality and intensity are all important factors
in the transcriptional regulation of a gene. The orientation of a DNA bend, relative to the
promoter and RNA polymerase binding position, has an enormous effect on the
transcription of a gene. By changing the position of a facilitated bend, its location and
orientation relative to a gene promoter is also changed. The orientation of a facilitated
bends, such as those induced by Sox2, may be the result of single nucleotide changes in
the binding site consensus sequences of DNA bending transcription factors.93 Changing
the orientation of a facilitated bend relative to a promoter will prevent optimal
interactions between distally bound proteins and the transcription machinery resulting in
decreased transcription levels.93,98

This phenomenon is explored later, in the

experimental validation of the role of DNA bending in transcription section.
In addition to the position and orientation of a DNA bend, the degree of a DNA
bend plays an important part in determining gene transcription levels. TBP binds to and
induces DNA bends in promoters that contain the TATA box consensus sequence, while
the SRY-related Sox2 protein binds to HMG box sequences. The bend induced by TBP
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at these binding sites varies in intensity, ranging from 30° to 106°.99-100 Sox2 induces an
83° bend in its binding site, while a mutation in the protein resulted in a bend angle of
46°.93 These studies indicate that there is a direct correlation between bend angle and
transcription. In addition, these studies indicated that the presence of an optimal bend
angle for transcription while bends that were too small or too large resulted in decreased
transcription levels.93,99-100 The induction of a bend by TBP at the TATA box was
described by a two state model in which transcription was not activated by TBP while a
DNA bend was only slightly induced, but upon the induction of an 80° DNA bend,
transcription became activated, demonstrating that transcriptional activation requires the
induction of a DNA bend of a certain magnitude.100

I.C.2. Experimental validation of the role of DNA bending in transcription
To analyze the role of protein-induced DNA bends in transcriptional regulation, a
number of replacement studies were preformed. In these studies, the binding sites of
various DNA-bending proteins were replaced with either intrinsically bent DNA or
binding sites for heterologous DNA-bending proteins. Gartenberg and Crothers replaced
the binding site for the DNA-bending protein CAP, located upstream of a lac promoter,
with phased A-tracts in vitro.101 Transcription was up-regulated by the presence of the
A-tract.

It was hypothesized that this up-regulation was due to the A-tract curve

mimicking the bend induced by normal CAP binding. When the curvature of the A-tract
was directed towards the opposite face of the helix, in opposition to a normal CAPinduced DNA bend, transcription was inhibited indicating that the orientation of a DNA
bend upstream of a gene could influence the expression levels of that gene. Similar
studies had been performed on the lac operon in vivo by replacing the binding site for
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DNA-bending CAP with various A-tract sequence combinations either in-phase (bend
occurs in the same direction as CAP) or out-of-phase (opposite direction compared to
CAP bending) with the start of the target gene.102 The results were the same as those
seen by Gartenberg and Crothers in their in vitro experiments; the A-tracts phased as the
natural CAP binding site up regulated the expression of the encoded gene, while the Atracts bending the DNA out-of-phase with the normal CAP bend displayed down
regulated gene expression. These studies also demonstrated the role of DNA bending and
its importance in the regulation of genetic transcription through the effects of changing
the phase of the bend. They illustrate the importance of the three-dimensional orientation
of DNA bends its role in gene regulation.
The down-regulation and total inhibition of expression demonstrated by out-ofphase DNA bends can be explained by both theories on the roles of DNA bending in
transcription. In terms of DNA wrapping, bending the DNA in the opposite direction of
that which facilitates transcription prevents the DNA from interacting with the RNA
polymerase in a manner to induce DNA wrapping. Bending the DNA opposite that of
transcriptional activation would also prevent distally bound proteins from being brought
into proximity for interaction at the promoter.
Later work revealed that A-tracts, while intrinsically bent, were also a binding site
for the sigma subunit of RNA polymerase, bringing into question the actual effects of the
intrinsic bend of an A-tract on transcription in both in vitro and in vivo environments.103
The authors suggested that the effects on transcription were due to the placement of a
new RNA polymerase binding site into the promoter. However, the fact that the activity
of promoter was dependent upon the relative orientation of the A-tract bend suggests that
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other factors may be involved besides the inclusion of a new RNA polymerase binding
site.

Figure 14. Protein replacement assay. The naturally occurring CAP binding site (CAP
bs) was replaced with a DNA bending protein binding site (DBP bs). CAP both bends
DNA and interacts with RNA polymerase (RNA pol) resulting in transcription. Orienting
the DBP bs as the CAP bs resulted in transcription through the bending action of the
DNA bending protein (DBP) without RNA pol interactions. Orienting the DNA bs such
that the DBP induced DNA bend was opposite that of CAP resulted in no transcription.
The ability of an A-tract to function as an RNA polymerase binding site
eliminated its use as an accurate tool to evaluate the role of DNA bending in
transcription. Other approaches were required to determine the function of DNA bends
in transcriptional regulation. A simple approach involved replacing the binding site of a
native DNA-bending protein with the binding site of a DNA-bending protein foreign to
the system (Fig. 14). Perez-Martin and Espinosa used this method to determine the
importance of a DNA bend induced by CAP in transcription in vivo.104 They replaced the
native CAP binding site in the fur operon with the binding site of an unrelated repressor
protein, RepA.

RepA is a known DNA-bending protein and heterologous to CAP,
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preventing CAP from interacting with both the RepA binding site and RNA polymerase.
Like the A-tract replacement experiments, placing the RepA site in the same phase as a
naturally occurring CAP binding site increased the interaction of RNA polymerase with
the promoter and transcription was initiated. Conversely, when the RepA site was phased
opposite to the normal CAP binding site orientation transcription was hindered.
Déthiollaz et al carried out a similar experiment, replacing the native CAP
binding site in a malT promoter with a binding site for an IHF protein in in vivo
experiments.105 Unlike CAP, the heterologous IHF protein did not interact with RNA
polymerase, limiting any effects on gene expression solely to the IHF-induced DNA
bend. Transcription was activated in the altered malT promoter when IHF was bound to
its binding site oriented as the original CAP binding site. These protein replacement
studies demonstrated the importance of the DNA conformation in transcription,
specifically the role of DNA bend orientation in relation to the start of a gene.
The role of DNA bending in transcription has also been analyzed through the
insertion of a DNA-bending protein binding site into a gene promoter, between the
binding sites of transcriptional factors whose interaction is required for transcriptional
activation (Fig. 15).23 The binding sites of YY1, LEF-1 and Sp1 proteins were evaluated
for their abilities to modulate transcription. The binding sites for these proteins were
inserted between eukaryotic transcriptional complex binding regions, where the RNA
polymerase bound, and activator/enhancer regions, which increase the rate of
transcription. All of the proteins were able to induce DNA bends at their inserted binding
sites. The bends induced by YY1, LEF-1 and Sp1 facilitated protein-protein interactions
between the transcriptional binding complex and proteins at the activator or enhancer
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regions, allowing transcription to proceed. Transcription only occurred when the induced
bend was properly oriented, allowing for interaction between proteins bound to the
transcriptional complex binding site and to the activator/enhancer binding site. Improper
phasing of the induced bend inhibited transcription by preventing the required
interactions of the distally located proteins in the promoter region.
The importance of the orientation of a DNA bend relative to the transcriptional
start site of a gene and its role in gene expression was also demonstrated by altering the
flexibility of sequence of DNA upstream of a gene. Scaffadi’s group created various
mutants of the DNA bending protein Sox2 and its respective binding site, located
upstream of an Fgf4 gene.93

These mutations showed a correlation between the

flexibility of DNA and gene expression in vivo. When a mutation granted DNA greater
levels of flexibility the level of transcription of the Fgf4 gene increased. Conversely,
decreased flexibility resulted in a loss of transcription and gene expression.

Figure 15. DNA bending protein binding site insertion into RNA polymerase
transcription factor binding region.
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I.D. Artificial DNA Bending
The ability of DNA bending to either up regulate or down regulate transcription
indicated that it could serve as a potential mechanism to artificially regulate genetic
expression to treat transcription related diseases. Targeting DNA as a means to regulate
transcription has advantages over other methods of artificial gene modulation.106-107 As
opposed to targeting gene products such as mRNA or proteins, which exist in abundance
in every cell, targeting DNA is attractive due to there being only a single target per cell.
Targeting DNA bending has an additional advantage that it does not require competition
with the potent binding of transcription factors.

Only the overall shape of the

transcriptional complex is important. On the other hand, targeting a specific sequence
within genomic DNA becomes difficult with the potential existence of multiple binding
sites, making sequence specificity a priority in designing DNA binding agents.

How does one induce a DNA bend? Within cells, DNA bending is present in the forms
of intrinsically bent DNA sequences and the binding of DNA bending proteins. These
methods would be impractical as mechanisms to artificially induce DNA bends.
Sequence-dependent DNA bending would require alteration of the genomic DNA
sequences, which would require the delivery and integration of a modified gene into the
genome. Using DNA-bending proteins would be less invasive, but their use has two
major drawbacks. First, the large size and multiple charges of many proteins make
transport into the cell and nucleus difficult. Secondly, a protein would need to be
engineered to target a specific sequence of DNA and retain its DNA bending ability.
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DNA bends have been artificially induced with non-protein ligands.

The

mechanisms these moieties use to induce bends fall into one of two opposing categories;
pull benders or push benders (Fig. 16).
Pull benders are composed of two DNA binding regions linked together with a
molecular tether. The only way that the two DNA binding regions can simulatenously
bind to DNA is if the DNA bends. Push benders bind to DNA and widened one of the
grooves of DNA, resulting in the DNA being pushed away from the moiety and bending
away from the bound ligand.
tether

PULL BENDING

PUSH BENDING
dsDNA

Figure 16. These are the general pull and push bending mechanisms. A pull bender is
an agent with two, tethered DNA binding regions that, once bound, pull and hold DNA
into a bent conformation. A push bender acts by binding into a DNA groove and
widening it, pushing the walls of the groove away from the agent and bending the DNA
away from the compound.
Tethered-triple helix-forming oligonucleotides, TFOs, are the quintessential
example of pull-bending DNA ligands. Tethered-TFOs are comprised of two singlestranded, triple-helix forming DNA arms connected by a variable length molecular tether
that does not interact with DNA.75,108-109 The utilization of tethered-TFOs in DNA
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bending strategies has been investigated using both parallel and antiparallel systems of
triplex formation.75,108-111 Both binding strategies used the same basic configuration; two
TFOs, targeted to sites located one helical turn apart on duplex DNA, linked together by
a linear molecular tether (Fig. 17). The tethered-TFOs bound to duplex DNA and
restricted the movement of the duplex DNA, holding it in a bent conformation.
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Figure 17. (A) The general structure of a tethered TFO, where the single stranded DNA,
ssDNA, can run either 5’ to 3’ or 3’ to 5’. (B) The linker subunits propylene glycol
phosphodiester, Pg, and triethylene glycol phosphodiester, Tg, utilized by Akiyama and
Hogan. (C) Bending of a DNA duplex by a TFO.
Akiyama and Hogan focused on tethered-TFO systems that utilized a variety of
molecular linkers which varied in length, from 18 to 44 rotatable bonds, to connect a pair
of antiparallel binding TFOs that were stabilized by T•AT and G•GC Reverse Hoogsteen
base pairs.107,109-110 The antiparallel orientation was selected due to its ability to form
stable triplexes under neutral conditions. A variety of linkers were tested based on the
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hypothesis that linkers with 25 or more rotatable bonds would not bend DNA, while a
linker shorter than 25 rotatable bonds would induce a DNA bend once the tethered-TFO
was bound.111
Akiyama and Hogan established a number of conclusions based on their work
with tethered-TFOs.108-110 They noted that the bends induced by the tethered-TFOs were
toward the minor groove of the DNA and reasoned that this bend directionality explained
why the free energy required to induce a bend in the DNA of around 60° with a tetheredTFO was less than they had projected. Akiyama and Hogan discerned that the sequence
of the region of DNA spanning between the TFO binding sites affected the magnitude of
the induced bend with AT-rich regions bending the most; though they claimed no relation
to intrinsic bending. They also demonstrated that shortening the length of the tetheredTFO linker resulted in a direct effect on the magnitude of the induced DNA bend; the
shorter the linker the greater the induced bend. A tethered-TFO with the shortest linker,
three propylene glycol phosphodiester units with a total of 18 rotatable bonds, bound to
duplex DNA with an AT-rich region between the TFO binding sites was able to induce a
bend of about 60° in the duplex structure. They demonstrated that a slight DNA bend
was detected when tethered-TFOs with linkers comprised of 30 and 33 rotatable bonds,
while linkers longer of this length were computationally projected to not possess the
ability to bend DNA.111 Akiyama and Hogan reasoned that these linkers were not fully
extended as expected, with probable gauche conformations in their linear structures, as
opposed to the expected anti- conformations. Suprisingly, unlinked TFOs were also
reported to induce slight bends in duplex DNA targets, though no explanation as to why
this occurred was given.
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The second category of DNA bending agents was the push benders. Push bending
is the result of introducing steric bulk into the minor groove of DNA such that the groove
widens and the DNA bends away from the molecule. Examples of such compounds
include ecteinascidin-743 (ET-743) and calicheamicin (Fig. 18).
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Figure 18. Ecteinascidin-743, ET-743, and calicheamicin-ζ1I.
ET-743 is a natural product possessing potent antitumor activity, specifically
against soft tissue sarcomas and advanced breast cancer.112-114

ET-743 covalently

attaches to DNA via the exocyclic N2 position of guanine. ET-743 binds to DNA triplets
with central guanine nucleotides, 5’- purine-G-C-3’ and 5’-pyrridine-G-G-3’.115-116 Once
bound in the minor groove, ET-743 protrudes perpendicularly from its binding site (Fig.
19). The bulk of projecting molecule exerts steric force on the walls of the minor groove,
widening it and causing the DNA to bend away from the molecule toward the major
groove.
Calicheamicin (Fig. 18) is an antibiotic and tumoricidal agent belonging to the
carbohydrate class of DNA binding compounds.117-119 Calicheamicin possesses both an
aryltetrasaccharide tail responsible for binding the compound to the minor groove of
DNA and an enediyne region that is responsible for cleaving DNA upon binding. In
order to bind to the minor groove of the DNA calicheamicin requires that the groove
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widen to accommodate the bulk of the enediyne region of the molecule.119 This widening
of the minor groove corresponds to a compression of the major groove on the opposite
face of the DNA.

Figure 19. ET-743 bound in the DNA minor groove.

II. STATEMENT OF THE PROBLEM AND OVERVIEW OF EXPERIMENTAL
APPROACH
A number of diseases have aberrant gene expression.2-4,120-123 Thus, methods to
artificially regulate gene expression would be a tremendous benefit. The long term goal
of the projects presented here is to create sequence specific DNA bending agents to
artificially regulate genetic expression (Fig. 20).

These agents will induce a bend

upstream of the promoter region of a gene resulting in either up-regulation or downregulation of expression. The ability to artificially control the expression of a gene would
allow for the potential treatment of a number of diseases including cancer,1-3,120
cardiovascular diseases121 and sickle cell anemia.122-123
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opposite to transcription factor,
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Figure 20. Regulation of transcription using an artificial DNA bending agent. Induction
of a bend with an artificial DNA-bending agent similar to that of a DNA-bending protein
will result in an “in-phase” DNA bend and an up regulation of transcription. Bending
DNA contrary to that of DNA bending protein would result in an “out-of-phase” DNA
bend and a down regulation in transcription.
Previous studies showed that both intrinsic DNA bends and bends induced by
DNA binding proteins effected transcription levels with the orientation of the bend
relative to the start of a gene being a critical determinate for gene regulation.23,93,101-105
When the bend was oriented analogous to that caused by a naturally occurring
transcription factor or RNA polymerase, an orientation known as an in-phase bend, a
gene would be up regulated or activated.23,101-105 Conversely, an out-of-phase DNA bend,
oriented in the opposite direction, resulted in the down regulation or silencing of gene
expression.23,93,102,104
How can one bend DNA? There are two general methods to artificially bend
DNA, namely pulling DNA into a bent conformation or pushing it into bent
conformation. Pull bending is accomplished using a molecule which contains two DNAbinding domains. The only way in which the two domains can bind to DNA is if the
DNA bends. Push bending is accomplished through the widening of a DNA groove with
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a DNA binding agent. This results in DNA bending away from the bound moiety. The
work presented in this thesis is divided into two main projects, with each project
examining one of the two methods to artificially bend DNA. The first project focuses on
the artificial regulation of gene expression through DNA bends induced by tetheredTFOs. The second project involves the synthesis and investigation of a small, sequence
selective, minor groove binding agent that function as a push bender through the
introduction of bulk into the minor groove of a DNA target sequence.

II.A. Project 1: Tethered-TFOs and Gene Expression
The first project will address the hypothesis that a non-protein moiety could
regulate gene expression through the induction of DNA bending. This project is essential
in the development of artificial gene regulating agents as it will either validate or refute
the concept that DNA bending alone could influence gene expression and that this
influence could be achieved through artificial means.

We will use Akiyama and

Hogan’s tethered-TFO system to artificially induce DNA bending in a synthetic
promoter/gene system.108-110 After bending of the target sequence is verified, we will
examine the effects of bending on the expression of our target gene. The orientation of
the bend will be varied and we anticipate that proper orientation of the induced DNA
bends will result in either the activation or repression of the target gene (Fig. 21). The
above hypothesis is supported by previous studies utilizing intrinsically bent DNA and
DNA-bending proteins to study the relationship between DNA bending and gene
expression.23,93,101,104-105
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Figure 21. (A) Tethered-TFO bending DNA in-phase with a gene, causing the activation
of transcription. (B) Tethered-TFO bending DNA out-of-phase with a gene resulting in
the repression of transcription.
The sequence of the oligonucleotides and tethered-TFOs used in this study are
shown in figure 22. The tethered-TFO that induced the greatest DNA bend in Akiyama
and Hogan’s experiments, labeled in our studies as the short tethered-TFO (STFO), will
be used as the positive control.108-110 The negative control in our research will be the
tethered-TFO that was previously shown to display no DNA bending ability; we have
dubbed this moiety the long tethered-TFO (LTFO). The negative control will be used to
verify that any effects seen in our experiments will be due to DNA bending and not the
binding of the tethered-TFO to the DNA targets. We will also utilize “broken” versions
of these tethered-TFOs (bSTFO, bLTFO) where the molecular tether and one TFO region
will be separated from the other TFO (Fig. 22). These broken variants of the tetheredTFOs will be used to verify that any affects on gene expression will be due to DNA
bending and not the formation of DNA triplexes.
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STFO:
LTFO:
bSTFO:
bLTFO:

5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’
5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’
5’-GGTGGGGTGGGTGGG-3’ and 5’-PgPgPg-GGGTGGGTGGGGTGG-3’
5’-GGTGGGGTGGGTGGG-3’ and 5’-TgTgTgTg-GGGTGGGTGGGGTGG-3’

Figure 22. The tethered-TFOs that we will use in this project. The short tethered-TFO,
STFO, that will bend DNA and the long tethered-TFO, LTFO, which will serve as the
negative control tethered-TFO com from Akiyama and Hogan. The broken variants will
be called bSTFO and bLTFO. Pg represents a propylene glycol phosphodiester unit and
Tg represents a triethylene glycol phosphodiester unit; see Fig. 6 for structures.
Before testing the ability of tethered-TFOs to regulate gene expression, we will
first verify that the target tethered-TFO binding sequence can be bent by STFO and not
any of the other TFOs; LTFO, bSTFO and bLTFO. Gel mobility shift assays will be used
for tethered-TFO induced bend analysis. DNA fragments containing the most flexible
tethered-TFO target sequence used by Akiyama and Hogan will be used in these
assays.108-109 After establishing the bending ability of our tethered-TFOs, we will then
investigate the effects of the bends will have on gene expression when the bends are
induced in varied orientations upstream of a luciferase gene.
A series of plasmids containing the tethered-TFO target sequence used by
Akiyama and Hogan will be positioned upstream of a promoter region and a luciferase
gene (Fig. 23).108-109 By varying the distance between the tethered-TFO target sequence
and the transcriptional start site of the luciferase gene, the orientation, or phase, of the
induced bend relative to the gene will change as well. TFO:DNA complexes will be
subjected to an in vitro transcription/translation system. The expressed luciferase protein
will then be quantified through Western blot analysis. We will determine whether the
induced DNA bends have an effect on gene expression levels and, if so, determine the
role that the phase of a bend has on artificial regulation.
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A
5’-GGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGG-3’
3’-CCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCC-5’

B

Variable Length Region
For Phasing Bend
Tethered-TFO Target Region

Start Site of Transcription
Promoter

Luciferase Gene

Figure 23. (A) The target sequence for these tethered-TFOs. The triplex target regions
are highlighted in gray, while the center of the induced bend is underlined. (B) Region of
interest in plasmid series containing the tethered-TFO target, the variable length region to
phase the induced DNA bend, the promoter region and the start of the luciferase gene.
We expect to learn that artificially induced DNA bends can effect gene expression
and that the phase of the bend plays and important role in gene expression. This project
will serve to validate or refute the use of artificially induced DNA bends to regulate
genetic expression.

II.B. Project 2: A Sequence Selective Push Bender
A series of small molecules that will function as sequence selective DNA push
benders will be created in the second project. While tethered-TFOs pull DNA into bent
conformations that can artificially regulate the expression of a gene, proving the concept
of artificial gene regulation through induced DNA bends, they are poor pharmaceutical
candidates due to their size and the difficulties in the formation of DNA triplexes in
vivo.124 Artificial gene regulation accomplished by a small molecule capable of passing
through membrane barriers, selectively binding to a specific DNA target sequence and
inducing a bend at that site upon binding would be ideal.
Our proposed push bending compounds were designed to widen the minor groove
of a DNA target through steric interactions between the walls of the minor groove and a
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bulky moiety introduced by the binding of our compounds. This bending mechanism will
be coupled to a sequence specific, minor groove binding region to create sequence
selective push bending molecules.
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Figure 24. (A) The lead compound, netropsin. (B) The structures of the netropsin
analogues, 1, 2 and 3. The DNA minor groove binding region and phenyl bulk are
labeled.
We will synthesize and evaluate a series of compounds that will act as sequence
selective DNA push bending agents (Fig. 24). Our compounds (1, 2 and 3) were modeled
after the mechanisms of push benders such as ET-743 and calicheamicin, which
introduce a bulky functional group in the minor groove of DNA forcing the groove to
widen and bend the DNA. Our compounds will couple a DNA binding region modeled
after netropsin to a bulky region that will widen minor grooves upon binding. These
analogues consisted of three main regions; a DNA minor groove binding region, a
phosphate binding region and a bulky moiety.
The minor groove binding region of our compounds was modeled after the amidelinked, dual N-methylpyrrole binding region of netropsin. This region should direct
binding to AT-rich sequences based upon its similarity to netropsin. A phenyl-bearing
thiazole ring was substituted for the C-terminal N-methylpyrrole, and was oriented with
the thiazole sulfur directed toward the minor groove-binding edge of the structure. This
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substitution was done to ease the synthesis of our target compounds and to maintain the
AT-rich DNA sequence binding preference of netropsin.55
The second region common to all of our compounds was the phosphate binding
region located at the C-terminus of the structures. Although netropsin possessed a Cterminal amidine, we opted to use a single dimethylaminopropyl arm.

The

dimethylaminopropyl arm was one methylene unit longer than the amidine arms of
netropsin, granting the chain greater flexibility and greater freedom of movement to
interact with DNA backbone phosphates once our compounds were bound to the minor
groove. The dimethylaminopropyl arm used in our compounds had been previously used
by Dervan in the construction of various polyamide minor groove binders.125

The

substitution of a dimethylpropylamide tail for the amidine of the model compound will
result in a decreased basicity which will enhance transport into the cell should these
agents bend DNA as hoped.126-127
The bulky moiety that our compounds will introduce into the minor groove of
their DNA binding sites was a phenyl ring attached to the 4-position of the thiazole ring
of the DNA minor groove binding region of the structures.

The phenyl ring will

sterically interact with the walls of the minor groove, widening it, pushing the DNA into
a bend away from the bound compounds. Molecular modeling, by Dr. Steven Firestine
with Molecular Operating Environment (MOE), shows that this phenyl ring will be
projected perpendicularly from the minor groove binding region, maximizing steric
interactions within the groove (Fig. 25).
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A

B

Figure 25. (A) Netropsin bound in the minor groove of DNA (1DNE from PDB). (B)
Compound 1 modeled in the minor groove of DNA using MOE.
The N-terminal guanidine arm bound to N-methylpyrrole of the lead compound
netropsin was replaced by three different functional groups including a proton
(compound 1), a tert-butoxycarbonylamino group (compound 2), and a formamide group
(compound 3). The single proton at this position in compound 1 should provide insight
into the role that this position plays in the binding of our compounds to the minor groove
of the DNA by removing the hydrogen binding and phosphate backbone interactions
from this location. Conversely, compound 2 possessed the largest functional group at the
4-position of the N-methylpyrrole; a tert-butoxycarbonylamino group.

Previous,

unpublished work from our laboratory had shown that the t-butyl group could alter the
conformation of DNA. Thus, we were interested in examining whether the inclusion of
two potential DNA bending groups would enhance DNA bending. Finally, a formamide
was placed at the 4-position of the N-methylpyrrole in compound 3 in an effort to
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enhance binding affinity by including an additional hydrogen bond donor from the –NH
of the amide bond of the formamide.48,51
After synthesizing our compounds, they will be evaluated for their DNA binding
ability, sequence binding preference and their ability to bend DNA.

An ethidium

displacement assay will be used to determine binding ability and sequence preference.
We expect our compounds to maintain the AT-rich sequence preference displayed by the
lead compound, netropsin.

We also expect that the various analogues will possess

different binding affinities, with the formyl-capped compound 3 having the greatest
binding affinity. FRET analysis will be used to determine what effect, if any, our
compounds have on the conformation of a DNA target. We expect to see a level of
conformational distortion in DNA targets with the preferred DNA target sequence. These
studies will provide important information to the future development of small, sequence
selective DNA bending agents to artificially control the expression levels of target genes.

III. RESULTS
III.A. Project 1: Tethered-TFOs and Gene Expression
III.A.1. Construction of Required Materials
To investigate the role DNA bending played in gene expression, we utilized the
tethered-TFO system described by Akiyama and Hogan.108-110 This system required two
major components, namely a series of plasmids (pBLP) containing the target sequence
for the tethered-TFOs and the tethered-TFOs with varied linker regions.
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III.A.2. Construction of pBLP Plasmids
The plasmid series pBLP was constructed through the insertion of
oligonucleotides into a series of vectors derived from pBR322. The four plasmids of the
pBLP series included two main sequence regions; a binding site for our tethered-TFOs
spaced at various distances from a promoter sequence and a luciferase reporter gene.
With the necessary fragments, we constructed four plasmids; pBLP77, pBLP80, pBLP83,
and pBLP86. The nomenclature used for our plasmid series was derived from the
location of the bend relative to the start of the luciferase gene.

We constructed the

pBLP plasmid series in a stepwise fashion (Fig. 26).
The purpose of the pBLP plasmid series was to position a luciferase gene at
varying distances from the center of a target site for a tethered-TFO at which a DNA
bend would be induced. The helical nature of DNA means that varying the distance
between two points on a strand of DNA results in a different orientation of the bend
relative to the start of the gene. Assuming that our plasmids adopt the most common
form of DNA, B-DNA, each turn of the helix contains 10.5 base pairs. The pBLP
plasmid series varied the distance between the center of the DNA bend and the
transcriptional start of a luciferase gene by 3 base pair increments, ranging from 77 to 86
base pairs. This created four different phases of the bend in relation to the luciferase
gene (Fig. 27A). At 10.5 base pairs per turn difference between the different phases can
be calculated in terms of degrees (Fig. 27B).
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pBLP77:
pBLP80:
pBLP83:
pBLP86:
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•
TAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGA
CTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGA
GTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCTGGATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGA
GGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGA

B

Figure 26. (A) Stepwise diagram of the creation of the pBLP plasmid series. (B) The
sequences of plasmids pBLP77, pBLP80, pBLP83 and pBLP86. The tethered-TFO
binding sites are red, with the center of the bend is highlighted in red. The malT
promoter is under lined with the -10 region highlighted in gray and the -35 region is
highlighted in yellow. The luciferase gene starts at the +1 position, highlighted in green.
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77
102.86°
154.28°
51.42°

80
102.86°
102.86°
154.28°

83
154.28°
102.86°
102.86°
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51.42°
154.28°
102.86°
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Figure 27. (A) Phases of the pBLP series of plasmid, relative to the start of the
luciferase gene. Rotational degrees based on average of 10.5 bp/turn of the double helix.
(B) Table of degrees of difference between the various phases of the pBLP series.
The pBend plasmid, named due to the incorporation of the tethered-TFO target
sequence, served as a precursor to the rest of the pBLP series plasmids (Fig. 26). We
inserted the TFO target fragment into the pBR322 plasmid at the Nhe I and BamH I
restriction sites (Fig. 46).

The successful creation of pBend was verified through

restriction analysis at the unique Xho I restriction site, introduced into the plasmid with
the TFO target fragment.
The pBLP plasmid series was created through the systematic insertion of various
DNA fragments into the pBend plasmid. The first pBLP plasmid that we created was
pBLP77, through the intermediate pBP77 plasmid. The pBP77 plasmid was built by the
insertion of the promoter fragment into pBend at the Bgl II and Sal I restriction sites (Fig.
26). The overhang at the 5’-end of the promoter fragment was capable of ligation to both
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digested BamH I and Bgl II sites. In placing the promoter fragment at the Bgl II position
of pBend, the center of the tethered-TFO target sequence was located 77 base pairs
upstream from the Nco I restriction site, where the start site of a luciferase gene would
eventually be located. The promoter fragment not only positioned the luciferase insertion
site relative to the center of the tethered-TFO bend, but also incorporated the malT
promoter upstream of the Nco I insertion site for the luciferase gene. The unique Nco I
and Xba I restriction sites of pBP77, introduced with the promoter fragment, served as a
restriction analysis sites for verification of the pBP77 plasmid. Bgl II was also used in
verification of the successful creation of pBP77, where the lack of digestion indicated a
loss of the Bgl II restriction site, which in turn indicated the insertion of the promoter
fragment.
The pBLP77 plasmid, the first complete pBLP plasmid, was created through the
insertion of the luciferase gene into pBP77 (Fig. 26). The 1656-bp luciferase gene was
excised from the pGL3 plasmid at the Nco I and Xba I restriction sites and subsequently
inserted into the pBP77 plasmid at these same sites. The Nco I site of the pBP77
plasmid, the location of the transcriptional start site of the luciferase gene, was positioned
77 base pairs from the center of the tethered-TFO target sequence, where the bend in the
DNA would occur. The creation of pBLP77 was verified by restrictive digestion with
Xho I and comparison of plasmid length to a similarly digested pBP77 plasmid.
The pBLP83 plasmid, like the pBLP77 plasmid, was built in two steps: insertion
of the promoter fragment into pBend to create the intermediary pBP83 plasmid followed
by the insertion of the luciferase gene into pBP83 to create pBLP83. The pBP83 plasmid
was constructed by inserting the promoter fragment into the pBend plasmid, as was done
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with pBP77 (Fig. 26). Unlike pBP77, the promoter fragment was inserted into the Sal I
and BamH I restriction sites, as opposed to the Bgl II site. Contrasting promoter fragment
insertion at the Bgl II site, insertion at the BamH I site did not destroy the restriction site
sequence. The promoter fragment included the malT promoter as well as positioned the
Nco I site, for luciferase gene incorporation, 83 base pairs from the center of the tetheredTFO target sequence. We verified pBP83 through restriction analysis with Nco I and Xba
I enzymes. The integrity of the BamH I restriction site was also tested to verify proper
fragment insertion.
The pBLP83 plasmid was obtained through the addition of the luciferase gene
from the pGL3 plasmid into the pBP83 plasmid at the Nco I and Xba I restriction sites
(Fig. 26). The luciferase gene was positioned downstream of the malT promoter with its
transcriptional start site located 83 base pairs from the center of the tethered-TFO target
site, 6 base pairs further or about a half turn around the DNA double helix different than
in the pBLP77 plasmid. The luciferase gene in pBLP83 was phased opposite that of the
gene in the pBLP77 plasmid.

Successful incorporation of the luciferase gene was

confirmed through Xho I digestion and length comparison of the pBLP83 and pBP83
plasmids via gel electrophoresis.
The center of the tethered-TFO induced DNA bend was phased in two opposite
orientations, relative to the transcriptional start of the luciferase gene, in pBLP77 and
pBLP83 (Fig. 27). Phasing the gene in the intermediary positions was accomplished
through modification of the pBLP83 plasmid. The pBLP80 plasmid was created through
the insertion of the Phase 80 fragment, with a malT promoter, into the pBLP83 plasmid at
the Xho I and Nco I restriction sites (Fig. 26). The Phase 80 fragment altered the distance
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between the transcriptional start site of the luciferase gene and the center of the tetheredTFO target site, lessening the distance by 3 base pairs. The center of the tethered-TFO
induced bend was positioned 80 base pairs from the start of the luciferase gene in a phase
between those of the pBLP77 and pBLP83 plasmids (Fig. 27). The pBLP80 plasmid was
verified by restriction analysis with Kpn I and BamH I, where Kpn I cut the pBLP80
plasmid and BamH I did not. The Kpn I restriction site was introduced to pBLP80 with
the Phase 80 fragment, while the BamH I restriction site was lost when the Phase 80
fragment was incorporated.
The pBLP86 plasmid was constructed in the same manner as pBLP80. The Phase
86 fragment, with a malT promoter, was inserted intp the pBLP83 plasmid at the Xho I
and Nco I sites (Fig. 26 and 46). The Phase 86 fragment changed the position of the
transcriptional start site of luciferase to 86 base pairs from the center of the tethered-TFO
target site. This repositioning phased the center of the tethered-TFO bend opposite that
of the pBLP80 plasmid and intermediary to the pBLP77 and pBLP83 plasmids (Fig. 27).
The pBLP86 plasmid was verified with Kpn I and BamH I restriction analysis in the same
manner as pBLP80.

III.A.3. Construction of Tethered-TFOs
We used the tethered-TFOs of Akiyama and Hogan as bending moieties for our
experiments.108-109 We chose to use the tethered-TFO that had previously been shown to
achieve the maximum bend angle as our positive control and we have dubbed this the
short TFO or STFO (Fig. 28). The molecular tether used in this ligand was composed of
three propylene glycol phosphodiester units and contained 18 rotatable bonds between its
two triple helix-forming regions.

51

Short TFO (STFO)
5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’

Broken Short TFO (bSTFO)
5’-GGTGGGGTGGGTGGG-3’
5’-PgPgPg-GGGTGGGTGGGGTGG-3’

Propylene glycol phosphodiester unit (Pg)
O
R O P O
O

R'

Long TFO (LTFO)
5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’

Broken Short TFO (bSTFO)
5’-GGTGGGGTGGGTGGG-3’
5’-TgTgTgTg-GGGTGGGTGGGGTGG-3’

Triethylene glycol phosphodiester unit (Pg)
O
R O P O
O

O

O

R'

Figure 28. Sequences and molecular tether composition phosphodiester units. The
molecular tethers of the STFO and the bSTFO contained 18 rotatable bonds, while the
molecular tethers of LTFO and bLTFO each contained 44 rotatable bonds.
In addition to the DNA-bending positive control, STFO, we needed a negative
control. We selected the longest tethered-TFO that Akiyama and Hogan investigated as
our negative control.108-109 This long tethered-TFO, LTFO, possessed a molecular tether
composed of four triethylene glycol phosphodiester units with 44 rotatable bonds
between the triplex-forming oligonucleotide arms (Fig. 28). LTFO displayed no DNA
bending properties due to the length and rotational freedom of its molecular tether. The
triethylene tether of LTFO was long enough to span a helical turn of DNA and allow the
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formation of two triplexes without altering the conformation of the DNA. We used
LTFO as a negative control to separate any gene expression effects caused by simple
tethered-TFO binding from any alterations in gene expression related to DNA bending by
STFO.
We created an additional set of negative controls in the form of broken versions of
the two tethered-TFOs, bSTFO and bLTFO (Fig. 28). These consisted of two singlestranded DNA oligonucleotides.

These broken oligonucleotides were created to

determine whether or not bending was dependent upon tethering of two TFOs and
whether gene expression was altered simply by the formation of DNA triplexes.

III.A.4. DNA Bending by Tethered-TFOs
Prior to exploring the effects of tethered-TFO-induced DNA bends on gene
expression, we first examined the ability of our selected tethered-TFOs to bend or not.
We used gel mobility analysis to accomplish this. In this method DNA fragments of
identical length migrate through a gel to the same extent as long as the fragments have
the same shape. Different shapes (circles, linear and bent) migrate at rates inversely
proportional to the end-to-end distance of a DNA fragment; the shorter this distance the
slower the fragment will migrate through a gel matrix.128 Thus, DNA containing a bend
will migrate slower than linear DNA due to a shorter end-to-end distance.
We were unable to use the pBLP plasmids created above for gel mobility analysis
because the plasmid was greater than the persistence length of DNA. Thus, we PCR
amplified a region of the pBend plasmid to generate two target DNA bending fragments
each containing the tethered-TFO binding site at a different location relative to the ends
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of the fragment. Two sets of primers and subsequent PCR were used to produce two
129-base pair DNA target fragments (Fig. 29).

A
C1:5’-CTAGCTAGCTAGTAGGAGGG-3’
C2:5’-CGCGGATCCAGATCTGCTCG-3’
E1:5’-CGTGCTGCTAGCTAGT-3’
E2:5’-TGTAGGAGCTATAGGC-3’

B
center

end

Centered
TFO Target
center
end

centering
primers

pBend
end
primers

End-Located
TFO Target

Figure 29. (A) Sequences of PCR primers used to create the centered TFO target DNA
fragement, C1 and C2, and to create the end-located TFO target fragment, E1 and E2. (B)
PCR amplification of 149 bp centered and end-located TFO target fragments.
The C1 and C2 primers were used to amplify the TFO target DNA fragment with
a centrally located tethered-TFO target site. The presence of the bend directly in the
center of the fragment would create the shortest possible end-to-end distance and thus
correspond to the slowest possible mobility through a polyacrylamide gel. The E1 and
E2 fragments were used to create a DNA target with a tethered-TFO target sequence
located at one end of the fragment. A bend induced at this location would only affect the
end-to-end distance to a small degree and, likewise, slow fragment gel migration only
marginally.
The two target DNA fragments, centered and end-located, were complexed with
various tethered-TFOs and analyzed by non-dentauring PAGE.

Analyzing both the
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centered and end-located fragments allowed us to determine whether shifts in the gel
mobility of a complexed fragment was due to either DNA bending or another
phenomena, such as an increase in the molecular weight.

We expected to see the

mobility of the centered TFO target fragment complexed to STFO, slowed to a greater
extent than any other fragment complex.
We compared the migration of the uncomplexed tethered-TFOs, the uncomplexed
DNA fragments and the TFO:DNA complexes in a gel mobility assay (Fig. 30). The
tethered-TFOs were too small to be seen in our polyacrylamide gels and migrated off the
bottom of the gel.
The uncomplexed, centered TFO-target DNA fragment had mobility consistent
with its expected size. When coupled to STFO, the centered TFO-target DNA fragment
displayed the greatest loss of mobility of any DNA fragment:tethered-TFO complex,
running similar to the 225-bp band of the DNA ladder (Fig. 30, lane 5). In contrast,
complexes of the centered TFO-target DNA fragment and LTFO or either of the broken
tethered-TFOs, bSTFO or bLTFO, resulted in only a minor change in mobility when
compared to the uncomplexed DNA fragment.
The uncomplexed end-located TFO target DNA fragment migrated similarly to
the 125-bp band of the DNA ladder, close to its 129 bp length. The end-located TFO
target fragment migrated slowest when complexed to STFO with a migration similar to
175-bp fragment, not as slow as the centered TFO target:STFO complex.

When

complexed to LTFO and the broken tethered-TFOs, the end-located target DNA fragment
migrated as a 150-bp fragment, as did the complexes of these three tethered-TFOs and
the end-located TFO target fragment.
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A

B

Figure 30. The gel mobility assay gel picture. In the lane assignments C represents the
centered TFO target DNA fragment and E represents the end-located TFO target DNA
fragment. (A) Lane 1, 25-bp DNA ladder molecular marker; Lane 2, STFO alone; Lane 3,
LTFO alone; Lane 4, C alone; Lane 5, C + STFO; Lane 6, C + LTFO; Lane 7, E alone;
Lane 8, E + STFO, Lane 9, E + LTFO. (B) Lane 1, C alone; Lane 2, C + STFO; Lane 3,
C + bSTFO; Lane 4, C + LTFO; Lane 5, C + bLTFO; Lane 6, E alone; Lane 7, E +
STFO; Lane 8, E + bSTFO; Lane 9, E + LTFO; Lane 10, E + bLTFO.
The gel mobility studies showed that STFO had a large effect on the migration of
the DNA target fragments, particularly the centered target (Fig. 30). LTFO, with a longer
molecular tether than STFO behaved in the same manner as observed by Akiyama and
Hogan, thus validating its use as a negative control (Fig. 30).108-109 As expected, the
broken variants of our tethered-TFOs, bSTFO and bLTFO, were unable to bend DNA
also confirming them as acceptable control ligands (Fig. 30).
Are the observed changes due to changes in the shape of the TFO:DNA
complexes or due to the increased molecular weight of the complex? Comparison of the
TFO complexes with the centered and end TFO target DNA provide an answer.
Coupling the two TFO-target DNA fragments with STFO resulted in significantly slower
migration rates compared to their respective, unencumbered states. However, there is a
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significant difference between the STFO:C complex and the STFO:E complex. Since the
molecular weight for both complexes is the same, the difference in migration is best
explained by a difference in the conformation of the two complexes.
The angle of the STFO-induced DNA bend in the TFO-target DNA fragments
was calculated using equation 1 in which θ is the bend angle, μm is the relative mobility
of a DNA fragment when the bend is at its center and μe is the relative mobility of a DNA
fragment when the bend is at the end of the fragment.109

⎛μ
θ = 2 arccos⎜⎜ m
⎝ μe

⎞
⎟⎟
⎠

Equation 1

We calculated the induced bend angles for both the STFO and LTFO tethered-TFOs from
the gels pictured in figure 30A (Table II).

Table II: Bending Angle Calculations for Tethered-TFO Induced Bendsa
Sample
STFO
LTFO

μm
2.18
3.39

μe
2.79
3.39

θ
77.23
0.00

a

The relative mobilities, μm and μe, were measured in cm. The bend angles, θ, were
calculated with equation 1.
STFO was able to induce a DNA bend of 77.23°, while LTFO was unable to
induce any DNA bend. These results were similar to those reported by Akiyama and
Hogan; the STFO was able to induce a bend while the LTFO was not.108,110 There are,
however, differences in the degree that STFO bent our DNA target and that reported by
Akiyama and Hogan. We calculated a bend angle of 77°, while Akiyama and Hogan
determined that STFO induced a bend of about 53°.108,110 There are several possible
reasons for this difference in bend angle. First, our target fragments differed from those
used by Akiyama and Hogan. Our 129-bp DNA targets were amplified from our pBend
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plasmids using PCR, while Akiyama and Hogan used restriction enzymes to remove their
171 bp targets from their own plasmids.108-109

Our target fragment was below the

persistence length of DNA, while Akiyama and Hogan’s fragment was equal to or above
the persistence length.
Second, the composition of the spacer region of our respective DNA target
fragments is different from that previously used. We used a spacer region that contained
only GC base pairs which is reported to be the most flexible spacer of those tried by
Akiyama and Hogan.110 Akiyama and Hogan used a different, less flexible sequence for
their calculation of tethered-TFO-induced bend angle.

III.A.5. Regulation of Gene Expression by Tethered-TFO-Induced DNA Bending
After verifying that our tethered-TFOs could induce a bend in our DNA target, we
next determined whether these artificially induced DNA bends could regulate expression
of

a

reporter

gene.

We

conducted

this

experiment

using

an

in

vitro

transcription/translation system. This allowed us to avoid the problems of transporting
our TFOs into cells and also avoid the problem of verifying the formation of a triplex in
vivo.
We coupled the various tethered-TFOs with the four pBLP plasmids, and then
subjected the complexes to in vitro transcription and translation. We quantified the
luciferase produced by these complexes to determine the effect the tethered-TFOs, and
their conformational alterations, on gene expression.
The tethered-TFOs were coupled to linearized pBLP plasmids in a manner
analogous to the method used in the gel shift analysis. The pBLP plasmids (pBLP77,
pBLP80, pBLP83 and pBLP86) were linearized by digestion with the Nde I restriction
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enzyme to remove the conformational obstruction presented by supercoiling and thus
ease the formation of triplexes between the plasmids and the tethered-TFOs (Fig. 31).
The linearized plasmids and tethered-TFOs were combined in a one-to-one molar ratio
and allowed to complex overnight at 37°C. Control plasmids were subjected to the
coupling conditions in the absence of tethered-TFOs.

Figure 31. Nde I linearization of the pBLP plasmid series. The “~” on the circular and
linear plasmids represents the variable region that contains the malT promoter.
The luciferase gene of the linearized pBLP plasmid:tethered-TFO complexes was
expressed using the EcoPro T7 in vitro transcription/translation system system from
Novagen. This system utilized T7 RNA polymerase that was compatible with the malT
promoters present in our pBLP plasmid series. After incubation of our plasmid/tetheredTFO complexes with the EcoPro system for one hour at 37°C, β-galactosidase was added
to each reaction as an internal control. Each reaction was then heat denatured and
luciferase expression was analyzed by SDS-Page followed by Western analysis using
both anti-luciferase HRP-conjugated and anti-β-galactodidase HRP-labeled antibodies.
The Western blot was examined by chemiluminence using an ECL Western blotting kit
and photographed using the Kodak Digital Science Image Station.
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The amount of luciferase produced was determined by measuring the intensities
of both the luciferase and β-galactosidase protein bands using the Kodak ID Image
software. From these intensities we were able to calculate the amount of luciferase
expressed using equation 2; where Aluc is the amount of luciferase expressed (ng) in the
sample lane, Ib-gal and Iluc are the intensities of the β-galactosidase and luciferase bands,
respectively, and Ab-gal is the amount of β-galactosidase (ng) added to the sample lane
prior to running SDS-PAGE.

⎛ I b − gal
A luc = ⎜⎜
⎝ I luc

⎞
⎟⎟ A b − gal
⎠

Equation 2

We compared the amount of luciferase expressed by each plasmid in the presence
or absence of the various tethered-TFOs. We calculated the percent change for all of the
pBLP plasmids complexed with each of the tethered-TFOs according to equation 3 (Fig.
32).

⎛⎡A
⎞
⎤
% Change = ⎜⎜ ⎢ luc + TFO ⎥100 ⎟⎟ − 100
⎝ ⎣ A luc ⎦
⎠

Equation 3

Complexes of pBLP77 and STFO resulted in a 51% reduction of luciferase
expression, yet no statistically significant change was observed over basal levels for
complexes of pBLP77 with the other three tethered-TFOs (Appendix A). A statistically
significant loss in luciferase expression was also seen in pBLP86/STFO complexes.
When compared to the luciferase expression of the pBLP77/STFO complex, there was no
statistical difference between the expression loss in pBLP86 and pBLP77.
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A
Plasmid
pBLP77
pBLP80
pBLP83
pBLP86

STFO
-51.3 ± 19.3
31.1 ± 13.3
93.3 ± 23.5
-35.2 ± 4.6

LTFO
-5.9 ± 5.5
-1.4 ± 5.9
9.8 ± 6.4
-0.6 ± 3.1

bSTFO
-4.1 ± 5.3
-1.2 ± 7.5
10.8 ± 6.6
-0.1 ± 2.7

bLTFO
-4.0 ± 9.2
-0.2 ± 3.4
2.6 ± 5.6
-2.0 ± 4.1

B
125
100
75
% Change

50
25
0
-25

pBLP77

pBLP80

pBLP83

pBLP86

-50
-75
-100

Figure 32. Averaged percent change in luciferase expression from uncomplexed pBLP
plasmids. (A) Percent change in luciferase expression for each plasmid complexed to a
tethered-TFO as compared to the same, uncomplexed plasmid; all values are percentages.
(B) The green bars represent STFO complexes, the black bars represent LTFO
complexes, the blue bars represent bSTFO complexes and the white bars represent
bLTFO complexes. These are the averaged results of six assays for pBLP77 and pBLP83
and five assays for pBLP80 and pBLP86.
In contrast to the loss of luciferase expression seen in complexes of pBLP77 and
pBLP86, a marked increase in luciferase expression was observed when STFO was
complexed with either the pBLP80 or the pBLP83 plasmids. The increased expression
levels were elevated to 31.1% and 93.3%, respectively, above the corresponding basal
luciferase levels. These elevated expression levels were significantly different from the
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decreased luciferase expression levels witnessed in complexes of STFO and either
pBLP77 or pBLP86.

In contrast, there was no statistical difference in luciferase

expression for complexes of pBLP80 and pBLP83 with LTFO, bSTFO and bLTFO.
Indeed, when all complexes of LTFO, bSTFO and bLTFO are examined, there is no
statistically significant difference between the luciferase expression levels of any of the
complexes.
Our data indicates that tethered-TFO-induced DNA bends are able to affect the
levels of luciferase expression in the manner that we predicted. STFO, shown to induce a
DNA bend in our gel mobility studies, demonstrated the greatest effect when complexed
to the pBLP plasmids, whether increasing or decreasing the level of luciferase expression.
On the other hand, all of the negative controls, which are unable to bend the DNA, do not
significantly affect the expression of luciferase. The lack of a significant effect on
luciferase expression by LTFO indicates that the bend induced by STFO, and not some
other factor, is the most likely explanation for the observed change in luciferase
expression.
The luciferase expression experiment verified the role of DNA bending in
artificially regulating gene expression when the results were viewed in terms of bend
phasing. The pBLP plasmids were designed with varying distances between the center of
the tethered-TFO target sequence and the transcriptional start of the luciferase gene. The
variation in this distance correlated to a change of phase in the induced bend of the DNA
due to differences in the relationship of these two sites in terms of three-dimensional
orientation (Fig. 27). We expected to see an increase in luciferase expression when a
bend was introduced in one of the pBLP plasmids with a corresponding decrease in the
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pBLP plasmid that was phased opposite it.

In addition, intermediary effects were

expected for the other two plasmids of the series which are phased in between the
plasmids.

In our experiment the pBLP83:STFO displayed nearly double the basal

expression level of the uncoupled plasmid. On the other hand, pBLP77, with an induced
bend opposite the pBLP83 bend, displayed a loss of about half of the luciferase
expression seen in the basal expression of the gene in this plasmid. The intermediary
pBLP plasmids displayed luciferase expression levels less extreme than those seen in
pBLP83 and pBLP77 when bent by STFO.
The results of our gene expression assay were consistent with those of the
replacement studies that explored the role of DNA bending in gene transcription.102-105
As demonstrated in the replacement studies, gene expression was enhanced when
artificial DNA bends were introduced in one orientation, in the pBLP83 complex, in a
direction presumably analogous to those introduced by native DNA bending
proteins.23,93,102-105 Altering the orientation of the artificially induced DNA bend such
that its directionality was opposite that of the enhancing, or in-phase, orientation, resulted
in a loss of gene expression. This decrease or loss of gene expression due to an out-ofphase bend was also observed in the replacement studies.23,93,102,104

III.B. Project 2: A Sequence Selective Push Bender
We were able to demonstrate that the expression of a target gene could be
influenced, both up- and down-regulated, through phased DNA bends induced upstream
of the gene by tethered-TFOs. Unfortunately, tethered-TFOs are poor pharmaceutical
candidates.

Ideally, artificial gene regulation through DNA bending would be

63

accomplished through small molecules capable of passing through membrane barriers,
selectively binding to a specific DNA sequence and inducing a DNA bend upon binding.
These small molecules would function as push bending agents; widening the minor
groove of a DNA target upon binding. In the second project of this thesis we synthesized
three DNA push bending agents (Fig. 24), tested them for DNA binding preference and
the ability to induce a bend in a DNA target.

III.B.1. Synthesis of 2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5carboxylic acid (3-dimethylamino-propyl)-amide, 1
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Reagents: (i) EDCI, DMAP, DMF, room temperature, 62% yield; (ii) LiOH/methanol,
60°C, 75% yield; (iii) 3-(dimethylamino)propylamine, HBTU, NMM, DMF, 51% yield.
The construction of 1 (Scheme I) was accomplished by condensation of N-

methylpyrrole-2-carboxylic acid and ethyl-2-amino-4-phenyl-5-thiazole carboxylate
using standard peptide bond coupling conditions (EDCI, DMAP) as described by Boger
et al.129 The resulting product, 4, was hydrolyzed with 1N LiOH to generate the free
carboxylic acid, 5, in good yield. The addition of the necessary cationic tail was again
performed using standard peptide coupling conditions. We found that is was necessary to
use the more reactive HBTU and NMM as coupling conditions for the formation of the
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final peptide bond.130 Purification of the final product, 1, using standard silica gel
chromatography provided the desired material in 51% yield.

III.B.2. Synthesis of {5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2ylcarbamoyl]-1-methyl-1H-pyrrol-3-yl}-carbamic acid tert-butyl ester, 2

Scheme IIa
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Reagents: (i) EDCI, DMAP, DMF, room temperature, 52% yield; (ii) LiOH/methanol,
60°C, 72% yield; (iii) 3-(dimethylamino)propylamine, HBTU, NMM, DMF, 60% yield.
Condensation of 4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carboxylic

acid and ethyl-2-amino-4-phenyl-5-thiazole carboxylate using EDCI, DMAP generated
the desired product, 6 in 52% yield (Scheme II). Hydrolysis of the ethyl ester with
lithium hydroxide generated the acid, 7, which was reacted with 3-(dimethylamino)
propylamine under conditions similar to those for the preparation of 1 to yield the final
product 2 in 60% yield.
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III.B.3. Synthesis of 2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4phenyl-thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide, 3

Scheme IIIa
H3C
O

H

NH
H
N

O
N
CH3

a

H3 C

N CH3

O

S
N

HN
O

i, ii

NH
H
N

O

2

N
CH3

S
N

O

N CH3

HN
O

3

Reagents: (i) CH2Cl2, benzenethiol, TFA, room temperature; (ii) Ethanol, ethyl formate,
reflux, 73% yield.
The formamide derivative of 2, compound 3, was obtained as outlined in scheme
III. Deprotection of the Boc group with trifluoroacetic acid and benzenethiol yielded the
free amine which was immediately reacted with ethyl formate to yield 3 in 73% overall
yield.

III.B.4. DNA Binding of Compounds 1, 2 and 3
We used an ethidium bromide displacement assay to determine the binding
affinities and sequence preference of compounds 1, 2 and 3. Ethidium bromide (EtBr)
fluoresces when bound to DNA, but possesses only weak fluorescence in the absence of
DNA. Thus, displacement of bound EtBr from DNA by other DNA binding agents
would result in a decrease in the fluorescence signal. By measuring changes in the
fluorescence as a function of compound concentration, we were able to determine the
binding constants for each compound for each DNA target.
In this assay, we investigated the ability of our compounds to bind to three
different DNA targets; to an AT-rich sequence of DNA, a GC-rich sequence of DNA and
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ScaI-linearized pUC19 plasmid. The AT-rich and GC-rich DNA target sequences were
generated from an oligonucleotide that could adopt a hairpin structure (Fig. 33). The Sca
I-linearized plasmid was created by digestion of pUC19 with ScaI restriction enzyme and
was used as a representation of a random sequence of AT and GC base pairs.

A

B
A
5’-CGGGCGGC A
A
3’-GCCCGCCG A
A

A
5’-CGAAAAAC A
A
3’-GCTTTTTG A
A

Figure 33. The DNA hairpin targets investigated in the ethidium bromide displacement
assay, (A) the AT target and the (B) GC target.
The binding constants for compounds 1, 2 and 3 utilized a method published by
Boger, et al.129 The collected data was normalized to the background fluorescence of
ethidium bromide in assay buffer, while the maximum fluorescence (100%) was set equal
to the fluorescence of ethidium bromide bound to the various dsDNA targets prior to
titration of the compounds. The data collected as a function of the concentration of the
individual compounds were converted into a percentage of this maximum fluorescence,
after being normalized to the background (Fig. 34).
The binding constants for compounds 1, 2 and 3 were found using equation 4;
where Kcompound is the binding affinity of the drug to the target DNA, KEB is the binding
coefficient for ethidium bromide for the DNA targets, [EB] is the concentration of
ethidium bromide present, and [compound]50 is the concentration of drug that reduced the
fluorescence of the ethidium bromide/DNA complexes by 50%.

K compound =

K EB [EB]
[compound]50

Equation 4
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Figure 34. Plot of the change in fluorescence of ethidium bromide bound DNA targets in
the presence of increasing concentrations of our compounds; AT-hairpin, ▲; GC-hairpin, ■;
and the linear pUC19 plasmid, ●. (A) Compound 1. (B) Compound 2. (C) Compound 3.
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Table III: Binding Constants of Compounds 1, 2 and 3

a

Compound & Target a
Netropsin + 5'-AATT-3'
Netropsin + 5'-ATAT-3'
Distamycin + AT-hp
1 + AT-hp
1 + GC-hp
2 + AT-hp
2 + GC-hp
2 + pUC19
3 + AT-hp
3 + GC-hp
3 + pUC19

[Compound]50 (x 10-4 M)
1.6720
9.8650
5.8335
5.7950
6.7405
1.3965
9.0350
6.0900

Kcompound (x 106 M-1)
b
25.0
b
2.2
c
6.5
0.026
0.004
0.008
0.008
0.007
0.032
0.005
0.007

: hp represents hairpin DNA. b: Sidorova et al., 1995. c: Boger et al., 2000.

For our data, we used KEB of 10 x 106 M-1 for all calculations with [EB] at 4.4 x 10-6
M.129 The calculated binding constants are presented in table III along with the binding
constants of netropsin for two different AT target sequences and for distamycin for the
AT-rich DNA hairpin.48,129 Compounds 1 and 3 displayed binding preferences for the
AT-rich hairpin DNA over the other DNA targets as demonstrated by their binding
constants. Compound 2, on the other hand, showed no preference for a single DNA
target, binding to all three at comparable levels, all of which were less than that of
compounds 1 and 3 toward the AT-rich hairpin. Compounds 1, 2 and 3 all displayed
binding constants two or three orders of magnitude less than a related compound,
netropsin, towards the DNA targets.
Our compounds were designed with the goal of creating sequence specific DNA
minor groove push bending molecules.

The ethidium bromide displacement assay

verified that compounds 1 and 3 bound to DNA with a noticeable level of sequence
specificity. Compounds 1 and 3 displayed a five to six-fold greater preference for ATrich DNA sequences over GC-rich and random DNA sequences.

The sequence

indiscriminate, low level DNA binding displayed by compound 2 was most likely due to
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the tert-butoxycarbonylamino group at the head of the compound and the steric hindrance
that it presented, preventing the compound from binding in the minor groove at any site.
The lower binding constants, as compared to netropsin and distamycin, of compounds 1
and 3 could be related to the inclusion of the phenyl ring at the 4-position of the thiazole.
The bulk of the ring may have dramatically effected the positioning of our compounds in
the minor groove and the ability of the minor groove binding edge of the compounds to
fully interact with the floor of the minor groove. Other thiazole-containing lexitropsins
displayed an inability to bind to DNA, let alone AT-rich DNA sequences, though the
majority of these compounds contained a substituted thiazole ring configured such that
the nitrogen atom was on the minor groove binding edge of the compounds.130

III.B.5. DNA Bending by Compounds 1, 2 and 3
We determined the ability of compounds 1, 2 and 3 to alter the conformation of
DNA upon binding using fluorescence resonance energy transfer (FRET) analysis. FRET
measures the distance between two fluorescent dyes, located at the 5’- and 3’-ends of a
DNA target. Changes in the conformation of DNA, due to bending, should result in a
change in the FRET signal between the two dyes. Thus, changes in the FRET signal
upon drug binding would be indicative of DNA bending. We compared the fluorescence
levels of two identical dsDNA sequences end-labeled with different dyes in the absence
and presence of compounds 1, 2 and 3 (Fig. 35).
The target FRET DNA sequence was 19-bp in length with an AT-rich central
sequence.

This target sequence was selected due to the AT sequence preference

demonstrated by the compounds in the ethidium bromide displacement assay.
Fluorescein and tetramethylrhodamine were selected as our FRET dyes as these dyes
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A
5’-(6-FAM)GATGCCGAAATTCCGCTTC-3’
3’CTACGGCTTTAAGGCGAAG-5’

B
5’-(6-FAM)GATGCCGAAATTCCGCTTC
-3’
3’CTACGGCTTTAAGGCGAAG(TAMRA)-5’

Figure 35. The two fluorescently labeled DNA fragments for FRET analysis. (A) This
fragment contains only the FAM fluorescence donor moiety, while (B) contains both the
fluorescence donating FAM moiety but also the fluorescence accepting TAMRA moiety.
have been used by other research groups investigating conformational changes in
DNA.131 The first of our DNA target sequences, the donor fragment, possessed a single,
5’-terminal fluorescein moiety, FAM.

Our other target DNA fragment, the donor-

acceptor fragment, was labeled with a 5’-terminal FAM as a FRET donating group and a
3’-terminal tetramethylrhodamine, TAMRA, as a FRET acceptor.
Samples of each fragment were excited at 495 nm in the absence of the
compounds and the emission spectra for each were recorded from 500 nm to 700 nm.
The emission spectra for both the donor sequence and the donor-acceptor sequence can
be seen in figure 36. While the emission spectrum for the donor sequence contained a
FAM peak at about 520 nm, the spectrum of the donor-acceptor target contained two
peaks; one at about 520 nm corresponding to FAM and a second, smaller peak at about
580 nm corresponding to energy transfer to TAMRA. The FAM peak of the donoracceptor sequence spectrum was smaller than that in the donor sequence spectrum due to
fluorescence resonance energy transfer. After analysis of the two DNA sequences alone,
excess amounts of compounds 1, 2 and 3 were added, incubated and then excited at 495
nm. The emission spectra from 500 nm to 700 nm were then recorded (Fig. 36).
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Changes in the conformation of the DNA targets were calculated based on the
differences in the spectra of the DNA target in the absence and presence of the
compounds. The bending caused by the binding of our compounds was calculated by
comparing the conformations of the FRET DNA target fragments with and without the
compounds. To calculate these conformations, the efficiency of the energy transfer from
the donor moiety to the acceptor moiety was determined using equation 5.131

In this

D
was the integrated intensity of
equation E was the efficiency of energy transfer; Φ em

DA
emission from 510 to 530 nm of DNA duplex with only the donor moiety; Φ em
was the

integrated intensity of emission from 510 to 530 nm of donor-acceptor labeled DNA
duplex.
D
⎛ Φ em
⎜
E = 1 − ⎜ DA
⎝ Φ em

⎞
⎟⎟
⎠

Equation 5

The calculated efficiencies of energy transfer are shown in table IV.

The

efficiency of energy transfer decreased when any of the compounds were bound to the
DNA, though this loss in efficiency was greater for compounds 1 and 3 than compound 2.
The energy transfer between the FAM donor and the TAMRA acceptor was less efficient
when the FRET DNA target was complexed with any of our compounds.

Table IV: FRET Derived Bending Data for Compounds 1, 2 and 3
Compound
No compound
1
2
3

Ea
0.249 ± 0.015
0.156 ± 0.004
0.217 ± 0.008
0.162 ± 0.017

Rb (Å)
58.9 ± 0.7
65.0 ± 0.3
60.7 ± 0.5
64.5 ± 1.3

θc (°)
55.3 ± 2.7
24.8 ± 2.8
48.3 ± 2.1
28.5 ± 8.7

Δθd (°)
0.0
-30.6
-7.0
-26.8

a

: Efficiency of energy transfer; b: End-to-end distance; c: Bend angle from linear, where
linear is 0°; d: Change in bend angle from FRET DNA target fragment without bound
compound.
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Figure 36. FRET spectra of donor fragment and donor-acceptor fragment in the absence
and presence of the compounds; the donor fragment in the absence of the compounds (Δ)
and in the presence of the compounds (▲), and the donor-acceptor fragment in the
absence of the compounds (○) and in the presence of compounds (●). (A) Compound 1
data. (B) Compound 2 data. (C) Compound 3 data.
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The end-to-end distance of the FRET DNA fragments is indirectly related to the
efficiency of energy transfer. The more efficient the energy transfers within a DNA
fragment, the closer together the ends of the fragment.

The relationship between the

efficiency of energy transfer and the distance between the two fluorescent dyes is given
by equations 6 and 7.131

In these equations, E represents the efficiency of energy

transfer; R represented the end-to-end distance of interest; and R0 was the “critical
distance” at which energy transfer from donor to acceptor and spontaneous decay of
donor is of equal probability. R0 was a constant and is dependent upon the FRET pairs
chosen. For our system, R0 was 49 Å.

E=

1
⎡ ⎛ R ⎞6 ⎤
⎟⎟ ⎥
⎢1 + ⎜⎜
⎢⎣ ⎝ R 0 ⎠ ⎥⎦

⎛
R = R0 ⎜ 6
⎜
⎝

⎛ 1 ⎞ ⎞⎟
⎜ ⎟ − 1⎟
⎝E⎠ ⎠

Equation 6

Equation 7

The end-to-end distances calculated by equation 7 are shown in table IV. The
maximum end-to-end distance for the two DNA sequences used in this FRET analysis,
representing a completely straight strand of DNA, was 66.5 Å, based on the accepted
average distance of 3.5 Å/DNA bp. The calculated end-to-end distances showed an
unexpected trend. Upon addition of compounds 1, 2 and 3 the end-to-end distances of
the target DNA sequences did not decrease, as expected, but rather increased approaching
the maximum length of these DNA sequences. The increased end-to-end distances and
decreased efficiencies of energy transfer suggested that the FRET DNA targets were
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becoming more linear and, therefore, less bent. This appears to be opposite of our
original goal.

5’- 6-FAM

θ
R
TAMRA -3’

Figure 37. Relationship of end-to-end distance, R, of the FRET DNA fragments and
angle from linear, θ. Decreasing distance R results in an increase in the θ angle and,
conversely, increasing distance R results in a decrease in angle θ. The maximum distance
for R was the linear length of the DNA fragment, 66.5 Å, with a θ angle of 0°.
The end-to-end distance of the FRET DNA in the presence and absence of our
compounds allowed us to calculate the bend angles that were present in the various
complexes (Fig. 37). As the end-to-end distance of the DNA fragments decreased, the
fragment becomes more bent in relation to linear DNA. We assumed that our compounds
were exerting their effects from the direct center of the FRET DNA target fragments, the
center of the 5’-AAATT-3’ binding site, and we set the linear length of the FRET DNA
to be 66.5 Å(19-bp at 3.5 Å/bp). From these assumptions, we used equation 8 to
calculate the bend angle relative to linear DNA. In equation 8, θ is the bend angle as seen
in figure 37, R is the end-to-end distance of the DNA and R0 is the maximum linear
length of the DNA fragment (66.5 Å).
⎛ R
θ = 2 cos −1 ⎜⎜
⎝ R0

⎞
⎟⎟
⎠

Equation 8
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The unliganded DNA displayed a bend greater than any of the complexes with
our compounds. The bend in the DNA target fragment was calculated to be 55° from
linear. This bend was sequence derived and, therefore, intrinsic in nature. The AT-rich
target sequence located in the center of the DNA target was the most likely source of the
intrinsic bend due to both the increased flexibility of AT-rich sequences and the steric
interactions between the adjacent adenines causing a bend in the DNA as in an A-tract,
widening the major groove and bending the DNA toward the minor groove.72-73,78-80
Our compounds demonstrated a lower efficiency of energy transfer, a greater endto-end distance and a corresponding decrease in bend angle. The change in bend angle,
Δθ, was calculated as the difference between the bend angles in the presence versus the
absence of our compounds (table IV). As seen in table IV, compounds 1 and 3 appeared
to have straightened the bend of the DNA target sequence by about 30°. Compound 2,
which possess poor DNA binding ability, altered the bend of DNA by only about 7°.
Our compounds were designed as minor groove-binding push bending agents.
However, complexes of DNA and our compounds resulted in more linear DNA
fragments, as opposed to DNA fragments with DNA bending as expected. In order for
the statically bent sequence of DNA to obtain a more linear conformation a force
opposing the adenine-derived bend has to be applied to the DNA. It is known that the
adenine-derived DNA bend is caused by a compression of the minor groove of DNA.
Our compounds bind to the minor groove and widen it through interactions between the
minor groove walls and the phenyl ring present in our compounds. Pushing the minor
groove open in the intrinsically bent FRET DNA target, however, would result in a bend
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in opposition to the naturally occurring bend at the target site and would ultimately result
in forcing the DNA into a more linear conformation.

IV. DISSCUSSION
IV.A. Project 1: Tethered-TFOs and Gene Regulation
The objective of this project was to examine whether artificially-induced DNA
bends could affect gene expression. Our studies showed that STFO was able to bend
DNA and regulate gene expression to a far greater degree than the other tethered-TFOs
tested (Fig. 32). The effect of this regulation was dependent upon the distance between
the bend and the start of the luciferase gene. When STFO was coupled to pBLP77, the
plasmid with the shortest distance between the center of induced bend and the start of the
gene (77-bp), the greatest loss in gene expression was observed. However, when the
center of the bend was moved 6-bp farther (pBLP83), the induced bend was moved to the
opposite face of the DNA. At this position, the amount of luciferase expressed was
nearly doubled. This dichotomy was expected, confirming our hypothesis that nonprotein driven, DNA conformational changes alone could influence the expression of a
gene.
The data from the gene expression assay indicated that changing the distance
between the center of the tethered-TFO-induced DNA bend and the start of the luciferase
gene would result in a change in level of gene expression. Plotting the percent change in
luciferase expression as a function of the distance, in base pairs, between the center of the
tethered-TFO-induced DNA bend and the start of the luciferase gene, it is apparent that
77

there is a cyclic function to the data (Fig. 38). It is interesting to note that the same cyclic
function is observed for the relationship between distance and bend angle for intrinsically
bent DNA and is reminiscent of plotted gel mobility data for DNA fragments with
variably positioned DNA bends.109 This relationship lends credence to the fact that DNA
bending is directly related to gene expression.
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Figure 38. Graph depicting the experimental percent change in luciferase expression
versus the distance, in base pairs, between the center of the tethered-TFO induced DNA
bend and the start of the luciferase gene (black circles) and the curve from equation 10
showing changing expression levels as a function of bend phase as a result of distance
(black line).
The data outlined in figure 38 is best fit with a sine function. The general formula
for a sine curve is shown in equation 9. The result y is a function of x where A is the
amplitude of the sine curve, w is the period of repetition (in radians), φ is the phase shift
of the curve and B is the vertical shift of the sine curve.

y = A sin(wx − φ ) + B

Equation 9
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From equation 9 and the gene expression assay data (Fig. 32), equation 10 was
derived to describe the change in luciferase expression as a function of the distance
between the induced DNA bend and the luciferase gene.

E = 85 sin[0.5984 (b − 77 ) − 1.5708 ] + 15

Equation 10

In equation 10, E is the percent change in luciferase expression and b is the distance in
base pairs from the center of the tethered-TFO target sequence to the start of the
luciferase gene. The amplitude of the equation, A, was estimated to be about 85; the
period of the equation, w, was based on 10.5-bp/turn, and was equal to 2π/10.5 or about
0.5984; the vertical shift, B, was calculated to be 15; and the phase shift value, φ, was
calculated to be 1.5708. The phase shift value, φ, was set such that the trough of the
curve fell at 77-bp, the low point of the experimental data. Equation 10 best fit the
experimental data and fell within the experimental error for each data point.
Based on equation 10, the greatest loss in luciferase expression, -70%, would
occur when the center of the induced bend was positioned 77 base pairs upstream of the
start of the luciferase gene; and every 10.5-bp increment from this point. On the other
hand, the greatest increase in luciferase expression, +100%, would occur at 82.25-bp.
Since no base pair can occur at this point, it is impossible to achieve a 100% increase in
gene expression. The maximum achievable increase in luciferase expression would occur
at a distance of 82 base pairs between the center of the induced bend and the luciferase
gene with a +99.1% increase in gene expression.
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We have demonstrated that artificially-induced, phased DNA bends were able to
alter gene expression levels. How these induced DNA bends were influencing gene
expression remains to be answered. There are two theories that can explain how DNA
bending can change gene expression. These theories are DNA wrapping and RNA
polymerase interactions with proteins or DNA upstream of the start of the gene. Both
mechanisms have been described in the literature.
In both prokaryotic and eukaryotic systems, RNA polymerase has been shown to
wrap DNA around itself after it binds to the promoter. Previous studies have shown that
the DNA wraps about 300° around the polymerase.

To accomplish this, about 90

consecutive base pairs are needed to come into contact with the RNA polymerase.
Footprinting studies have shown that the base pairs range from the -70 to the +20
position.83,94-96
Induced DNA bends could have affected DNA wrapping either facilitating or
hindering the wrapping around RNA polymerase. The major difference between the
various TFO:DNA complexes was whether a DNA bend had formed and what was the
orientation of that bend. Both of these factors could affect DNA wrapping. The out-ofphase, STFO-induced bends seen in complexes with pBLP77 and pBLP86 plasmids may
have altered the conformation of DNA such that it was unable to wrap around RNA
polymerase (Fig. 39A). The end result of this would be a weaker RNA polymerase:DNA
complex, which would lead to a decrease in the efficiency of transcription. Conversely,
the increased levels of luciferase expression witnessed in the pBLP80:STFO and
pBLP83:STFO complexes could also be explained by facilitating DNA wrapping around
the RNA polymerase (Fig. 39B). Facilitating DNA wrapping would decrease the energy
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required, which would enhance binding of RNA polymerase and thus increase
transcription. The other TFOs that have no effect on DNA conformation, LTFO, bSTFO
and bLTFO, should have no effect on either RNA polymerase binding or on DNA
wrapping (Fig. 39C).

A

B

C

Figure 39. Role of tethered-TFO induced DNA bending in DNA wrapping. (A) Out-ofphase bends prevent DNA wrapping around RNA polymerase resulting in the down
regulation of luciferase expression. (B) In-phase bends facilitate DNA wrapping that
enhances luciferase expression. (C) Tethered-TFOs that did not bend DNA allow DNA
wrapping to occur normally with baseline levels of luciferase expression.
Another mechanism by which tethered-TFO induced DNA bends could have
affected the luciferase expression involved the inhibition or activation of protein-protein
or protein-DNA interactions to RNA polymerase (Fig. 40). Again, the overall effect on
gene expression would be dependent on the orientation of the bend relative to the start of
the gene. An in-phase bend would facilitate interactions with upstream proteins or DNA,
which in turn would increase gene expression. Conversely, an out-of-phase bend would
hinder interactions and result in the down regulation of luciferase expression. TetheredTFOs that did not affect the conformation of DNA would have no affect on the
occurrence of these interactions and, consequently, luciferase expression would occur at
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the baseline level. Although we cannot definitively rule out this mechanism, we believe
that it is high unlikely to occur in our system for two reasons. First, our vectors were not
designed with binding sites for transcription factors. Second, the EcoPro T7
transcription/translation system lacks these transcription factors due to the kit being
designed to function with only a T7 or E. coli promoter.
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Figure 40. Role of phased DNA bends in facilitating interactions between RNA
polymerase, RNA Pol, and upstream proteins, UP. (A) Linear DNA without tetheredTFOs or with non-bending tethered-TFOs display normal levels of transcription. (B) Inphase bends facilitate contact between RNA Pol and UP, up activating transcription. (C)
Out-of-phase bends inhibit transcription by preventing interaction between the proteins.
Regardless of how tethered-TFO induced DNA bends were affecting gene
expression, these results demonstrate that the induction of a DNA conformational change
upstream of a gene can alter gene expression. This method of gene control presents a
single mechanism by which a gene can be either activated or inhibited, dependent on the
location and subsequent phase of an induce bend. This mechanism offers the potential
for the development of a new class of gene expression controlling pharmaceutical agents.
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Our study demonstrated the ability to alter gene expression with the induction of
phased DNA bends upstream of RNA polymerase bind. The future development of
pharmaceutical agents for the treatment of gene expression related diseases will require
further exploration of this mechanism in eukaryotic systems. Nucleosome packaging
plays an important role in eukaryotic transcription and will have to be dealt with for gene
expression to be altered by artificially induced DNA bends.132-133

IV.B. Project 2: A Sequence Selective Push Bender
The tethered-TFO bending project verified that a non-protein moiety could induce
a bend in DNA and affect the expression of the gene, validating the artificial induction of
phased DNA bends as a mechanism to alter gene expression. It is unlikely, however, that
tethered-TFOs themselves would be useful medicinal agents due to their size and
complexity. The ideal agent would be a small molecule that could bind to a specific
sequence of DNA and induce a bend to alter gene expression in the manner demonstrated
by the tethered-TFOs. Thus, the objective of the second project was to explore the design
of small molecule, sequence specific DNA bending agents.
Currently, there are a number of compounds that are capable of binding to DNA
and some of these display sequence selectivity. Among the most selective DNA binders
are the polyamide and lexitropsin classes of compounds. These compounds interacted
with hydrogen bond donors and acceptors presented by nucleotides in the minor groove
of the DNA duplex. Polyamides have served as useful molecules to delivery other
functions to DNA and thus were logical choices for the construction of DNA bending
agents.
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In contrast to the minor groove binding agents, there are relatively few molecules
that are capable of changing the conformation of DNA and most of them display poor
sequence selectivity. However, we used some of the design principles found in existing
DNA bending agents like ET-743 to construct our agents. ET-743 induces a
conformational change in DNA through steric interactions between minor groove walls
of the binding site and the perpendicularly displayed bulky aromatic ring system of the
molecule.

The bulk of the ring system widened the minor groove causing a

corresponding compression of the major groove on the opposite face of the DNA,
resulting in a DNA bend.
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Figure 41. Netropsin and the three analogues; 1, 2 and 3.
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We designed a series of compounds that incorporated the minor groove binding
specificity of polyamides with the DNA bending mechanism of compounds like ET-743.
Compounds 1, 2 and 3 included structural features of the minor groove binding agent
netropsin and like netropsin, our molecules bound to AT-rich DNA sequences (Fig. 41).
Compounds 1-3 were also designed to present bulky group into the minor groove of their
target in a manner analogous to ET-743. We chose to use a phenyl ring since the phenyl
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group would adopt a perpendicular orientation relative to the planar shape of the rest of
the molecule which would allow it to sterically interact with walls of the minor groove.
The compounds were synthesized in a straightforward manner analogous to other known
minor groove binding agents.
An ethidium bromide displacement assay was used to determine the binding
constants and sequence preferences of our compounds. Compounds 1 and 3 displayed
the expected preference for AT-rich DNA sequences with 1 displaying about a 7-fold
preference for the AT-rich target while 3 showed a 6-fold preference. Compound 2
demonstrated similar binding constants for all three DNA targets indicating that it was
most likely a non-specific binding agent. The presence of a bulky group in the Nterminal position in compound 2 must have been great enough to prevent the compound
from correctly positioning itself in the minor groove of an AT base pair.
The observed binding constants for all three compounds were 300 to 2000-fold
less than the reported binding constant of netropsin for AT-rich DNA.48 Our compounds
differ from the model molecule, netropsin, by the substitution of 4-phenyl-thiazole for an
N-methylpyrrole and utilization of different N- and C-terminal tail groups.

The

discrepancy in binding affinities between that reported for netropsin and our compounds
could be attributed to these replacements.
The thiazole of our compounds incorporated a sulfur atom in place of a vinyl at
the 1 position of the ring. The sulfur atom was larger than the original carbon atom and
may have prevented optimal alignment of our compounds in the minor groove of the
target DNA. The incorporation of thiazoles into the minor groove binding region of a
polyamide compound had previously been used to selectively target the adenine over the
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thymine of an AT base pair, due to alterations in the alignment of the N-terminal amide –
NH in the minor groove.55 This sequence preference may also have affected the binding
of our compounds to an AT-rich DNA target by our compounds not aligning with the
minor groove in the most advantageous manner.
In addition, the phenyl ring attached to the minor groove binding region of our
compounds protruded perpendicularly from the minor groove, as seen in molecular
modeling (Fig. 25). The lower binding affinities of compounds 1-3 could have been the
result of steric interactions between the phenyl ring and the minor groove, shifting the
position of the compounds in the minor groove resulting in less favorable alignment with
the hydrogen bond acceptors in the minor groove.
Netropsin possessed a guanidine tail at its N-terminus. This tail interacted with
the minor groove of DNA by forming hydrogen bonds between the protonated tail and
the N3 position of adenines.134 The replacement of this group with a proton or a bulky
chain would prevent the formation of this hydrogen bond, resulting in the poorer binding
affinities observed for these compounds toward the minor groove of AT-rich DNA
sequences. The formamide group at the N-terminus of compound 3 also lacks this
additional hydrogen bond, but maintains an amide –NH at this terminus to form a
hydrogen bond with adenine N3 and thymine O2 groups in the minor groove, a feature
missing from compound 1.
Like the N-terminal guanidine, the C-terminal amidine of netropsin also played a
role in binding to the minor groove of AT-rich DNA sequences, specifically to the N3
position of adenines.134 Dimethylaminopropylamide, like the C-terminal amidine tail of
netropsin, is protonated under physiological conditions allowing it to interact with the
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minor grooves of AT base pairs.126

The replacement of this amidine tail with a

dimethylaminopropylamide tail has been shown to result in decreased binding
affinities.126-127 This decrease, however, was not severe enough to explain the 300 to
2000-fold difference in binding affinities between our compounds and netropsin. The
dimethylaminopropyl-amide tail has been utilized in a number of polyamide and
lexitropsin derivatives due to the increased hydrophobicity which increases membrane
transport and forms favorable hydrophobic controls with the methylenes of the sugar
group in the minor groove.125
The inclusion of a bulky group into compounds 1 and 3 was done to induce a
bend in DNA by widening the minor groove through steric interactions. Using FRET, we
had expected to see an increase in the efficiency of energy transfer in the presence of our
compounds, indicating the induction of a bend. This would correlate to DNA bending.
However, we observed the opposite effect. All three compounds decreased the efficiency
of energy transfer between the fluorescent donor and acceptor. These lower efficiencies
corresponded to an increase in the end-to-end distance with the drug:DNA complex being
1 to 5 Ǻ longer than the uncomplexed DNA.
The longer end-to-end distance indicates that the binding of compounds made the
DNA targets more linear. Consequently, this suggests that the unliganded DNA target
was bent. This conclusion is validated based upon the efficiencies of energy transfer of
the uncoupled target DNA fragment. These measurements reveal that the end-to-end
distance of our target DNA fragments is about 58.9 Å, shorter than a completely linear
DNA strand with the same number of base pairs (66.5 Å). We believe that the AT-rich
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DNA sequence in the center of the DNA target fragment may have been the source of the
bend. Previous researchers have noted that A-rich DNA sequences can bend.
Compounds 1 and 3, and to a lesser degree compound 2, lessened the intrinsic
DNA bend of the DNA target (Table IV). Complexes of the DNA and compounds 1 and

3 displayed DNA bends of 25° and 29°, respectively, compared to 55° for the
uncomplexed DNA. Complexes of compound 2 lessened the intrinsic bend to 48°.
There are three possible mechanisms for how our compounds could have
converted the intrinsic bend of the DNA into a more linear conformation (Fig. 42). The
first is that these agents bind only to the linear conformation of DNA. This would
stabilize the linear DNA:drug complex which in turn would shift equilibrium to the linear
complex resulting in a decreased FRET signal.

However, for this to occur, our

compounds would have had to cause minor groove compression at the binding site (Fig.
42A). The presence of the phenyl ring of the compounds seems incompatible with a
compression of the minor groove.
The second possibility is that the intrinsic bend observed in our target DNA is due
to induced minor groove compression, where binding of the drug into the minor groove
results in widening the minor groove and straightening the DNA (Fig. 42B).

This

mechanism would be consistent with the observation of minor groove compression in
intrinsic bends and would also be compatible with our proposed mechanism of action for
our agents. Such a conclusion would have to be validated by additional experiments to
determine the mechanism of the intrinsic bend in our target DNA fragments and also a
more detailed study of different steric groups in the compounds.
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Figure 42. Our compounds could straighten the intrinsically bent 19-bp FRET DNA
target by narrowing a widened minor groove (A), by widening a narrowed minor groove
(B) or by creating a second, opposing, bend in the DNA at a different position from the
intrinsic bend (C). θ represents the bend angle of the DNA target in the absence of
compound, the red arrow indicates where the compound binds to the DNA and θ'
represents the closer to linear bend angle of the DNA target coupled to compound.
The third possible mechanism is that the intrinsic bends of the DNA target
fragments may have occurred at a location other than the binding site of compounds 1, 2

89

and 3 (Fig. 42C). This model would be especially likely in the event of the intrinsic bend
occurring at a location other than the AT-rich central sequence. In this situation, the endto-end distance of the DNA fragment was lengthened by the compound-induced second
bend in the opposite direction as the intrinsic bend (Fig 42C).

The calculations of the

magnitude of the bends induced by our compounds in this model are far more complex
and would require numerous other experiments.
The goal of this project was to create small molecules able to selectively bind to a
DNA sequence and induce a DNA bend upon binding. Using the polyamide netropsin as
a parent compound we synthesized three compounds that combined the sequenceselective binding of netropsin-related compounds and a DNA bending mechanism similar
to that of ET-743. Our compounds displayed a preference for AT-rich sequences, though
they lacked the binding affinity of netropsin toward this sequence. The conformation of
DNA, as measured by the end-to-end distance of the DNA target changed when the
compounds were bound to DNA. This suggests that our agents have the ability to alter
the conformation of DNA. However, this alteration was more complex than expected.
The DNA target possessed an intrinsic bend that was straightened when compounds 1, 2
and 3 were bound. This may have been accomplished through the DNA bending activity
of the compounds, with bends induced counter to the intrinsic bends already present. In
this situation our compounds functioned as intended; compounds 1, 2 and 3 were able to
selectively bind to a DNA target and induce a DNA bend upon binding.
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V. MATERIALS & METHODS
V.A. Project 1: Tethered-TFOs and Gene Expression
Chemicals and Enzymes.

The deoxynucleotides and linker phosphoramidites were

purchased from Glen Research. The unbroken TFOs, STFO and LTFO (Fig. 45), were
purchased from TriLink Biotechnologies (San Diego, CA). The oligonucleotides were
purified by extraction from a polyacrylamide gel.

Restriction endonucleases, T4

polynucleotide kinase, Quick T4 DNA ligase, Taq DNA polymerase and pBR322 were
purchased from New England BioLabs (Ipswich, MA).
purchased from Novagen (San Diego, CA).

The EcoPro T7 kit was

Recombinant firefly luciferase was

purchased from Calbiochem (San Diego, CA). The β-galactosidase was from SigmaAldrich. The anti-luciferase-HRP conjugated antibodies and the anti-β-galactodidaseHRP-labeled antibodies were from Research Diagnostics, Inc. (Concord, MA).

Oligonucleotide Syntheses. The tethered-TFOs, STFO and LTFO, the broken TFOs,
bSTFO and bLTFO (Fig. 43), the PCR primers (Fig. 43) and the oligonucleotides used to
construct the plasmid inserts (Fig. 44 and 45) were synthesized on a PerSeptive
Biosystems Expedite Nucleic Acid Synthesis System using standard conditions. The
oligonucleotides were purified by 13% denaturing PAGE followed by solid phase
extraction.
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A
STFO: 5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’
LTFO: 5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’
bSTFO:5’-GGTGGGGTGGGTGGG-3’ and 5’-PgPgPg-GGGTGGGTGGGGTGG-3’
bLTFO:5’-GGTGGGGTGGGTGGG-3’ and 5’-TgTgTgTg-GGGTGGGTGGGGTGG-3’

B
C1:5’-CTAGCTAGCTAGTAGGAGGG-3’
C2:5’-CGCGGATCCAGATCTGCTCG-3’
E1:5’-CGTGCTGCTAGCTAGT-3’
E2:5’-TGTAGGAGCTATAGGC-3’

Figure 43. (A) The TFOs used in the assays. Pg represents a propylene glycol
phosphodiester unit, while Tg represents a triethylene glycol phosphodiester unit. (B)
Sequences of PCR primers C1, C2, E1 and E2.
Plasmid Insert Construction. The plasmid inserts (Fig. 44) were synthesized in four
parts (Fig. 45) as described below. Each oligonucleotide (100 pmol) was treated with T4
polynucleotide kinase (10 units) at 37°C for 1h and the four oligonucleotides for each
insert were combined, annealed by a heating-cooling cycle of 95°C for 5 min followed by
slow cooling to 25°C at a rate of 1°C/min. The plasmid inserts were ligated into whole
units by treatment with Quick T4 DNA ligase (10 units) at room temperature for 5 min.

Plasmid Construction. The plasmids were digested with restriction enzymes
corresponding to the plasmid insert to be incorporated. The cut plasmids were purified
on an agarose gel. The cut plasmid (50 ng) and the plasmid insert (5x the molarity of the
cut plasmid) were ligated together with Quick T4 DNA ligase (10 units) at room
temperature for 5 minutes. Ligated plasmids were then amplified by transformation of
DH5α E. coli cells cultured on ampicillin containing agar plates. The colonies were then
grown overnight via inoculation into ampicillin containing LB media. Minipreps of the
inoculations were performed to acquire the amplified plasmid DNA.

pBend was
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constructed by inserting the TFO target DNA fragment (Fig. 44 and 45) into the
NheI/BamHI site of pBR322.

Insertion was confirmed by XhoI digestive analysis.

pBLP77 was constructed by first inserting the promoter DNA fragment (Fig. 44 and 45)
into the BglII/SalI site of pBend to create pBP77. pBP77 was verified by XbaI digestive
analysis.

The pBLP77 was constructed by inserting the luciferase gene of pGL3

(Promega) into the NcoI/XbaI site of pBP77. Insertion was verified by digestive analysis.
pBLP83 was constructed by first inserting the promoter DNA fragment (Fig. 44 and 45)
into the BamHI/SalI site of pBend to create pBP83.

pBP83 was verified by XbaI

digestive analysis. The pBLP83 was constructed by inserting the luciferase gene of
pGL3 into the NcoI/XbaI site of pBP83. Insertion was verified by digestive analysis.
pBLP80 was constructed by inserting the Phase 80 DNA fragment (Fig. 44 and 45), first
cut with XhoI and NcoI, into the XhoI/NcoI site of pBLP83. Insertion was verified by
KpnI and BamHI digestive analysis. pBLP86 was constructed by inserting the Phase 86
DNA fragment (Fig. 44 and 45) , first cut with XhoI and NcoI, into the XhoI/NcoI site of
pBLP83. Insertion was verified by KpnI and BamHI digestive analysis.
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A
Nhe I
Xho I BglII BamH I
5’-CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCTG
-3’
3’GATCATCCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCCACGAGCTCGTCTAGACCTAG-5’

B
Bgl II-BamH I
Nco I Xba I Sal I
5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGTCTAGAG
-3’
3’GATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCAGATCTCAGCT-5’

C
Xho I
Kpn I
Nco I
5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’
3’-GGCAGGAGCTCGTACCATGGGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’

D
Xho I

Kpn I

Nco I

5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’
3’-GGCAGGAGCTCGTAGCCATGGTAGCTGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’

Figure 44. (A) The TFO target fragment sequence. The Nhe I overhang is highlighted in
yellow; the tethered-TFO target sites are in red text with the center of the bending region
highlighted red; the Xho I site is highlighted in green; the Bgl II site is highlighted in
pink; and the BamH I overhang is highlighted in blue. (B) The promoter fragment
sequence. The Bgl II/BamH I compatible overhang is highlighted in blue; the malT
promoter region is underlined with the -10 region highlighted in gray and the -35 region
highlighted in yellow; the Nco I site is highlighted in red; the Xba I site is white text
highlighted in dark green; and the Sal I overhang is highlighted in black with white text.
(C) The Phase 80 fragment sequence. The Xho I site is highlighted in green; the Kpn I
site is white text highlighted with purple; the malT promoter region is underlined with the
-10 region highlighted in gray and the -35 region highlighted in yellow; and the Nco I site
is highlighted in red. (D) The Phase 86 fragment sequence. The Xho I site is highlighted
in green; the Kpn I site is white text highlighted with purple; the malT promoter region is
underlined with the -10 region highlighted in gray and the -35 region highlighted in
yellow; and the Nco I site is highlighted in red.
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TFO Target DNA Fragment:
5’-CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCTG
-3’
3’GATCATCCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCCACGAGCTCGTCTAGACCTAG-5’
Single-stranded oligonucleotides to create TFO-target fragment:
TFOt1: 5’-CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCCCGGGAGG-3’
TFOt2: 5’-GAGGGGAGGTGCTCGAGCAGATCTG-3’
TFOt3: 5’-GATCCAGATCTGCTCGAGCACCTCCCCTCCCTCCCGCGCC-3’
TFOt4: 5’-GGCGCCCTCCCTCCCCTCCTACTAG-3’

Promoter DNA Fragment:
5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGTCTAGAG
-3’
3’GATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCAGATCTCAGCT-5’
Single-stranded oligonucleotides to create promoter fragment:
TT1: 5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACC-3’
TT2: 5’-TTATAACCATGGTCTAGAG-3'
TT3: 5’-TCGACTCTAGACCATGGTTATAAGGTCGGCCAGAAACC-3’
TT4: 5’-TTTCTAATGCAAGCGTATAG-3’

Phase 80 DNA Fragment:
5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’
3’-GGCAGGAGCTCGTACCATGGGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’
Single-stranded oligonucleotides to create Phase 80 fragment:
P84a: 5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAG-3’
P84b: 5’-GTTTCTGGCCGACCTTATAACCATGGCATG-3’
P84c: 5’-CATGCCATGGTTATAAGGTCGGCCAGAAACCTTTCTAATGCAAGC-3’
P84d: 5’-GTATAGGGTACCATGCTCGAGCACGG-3’

Phase 86 DNA Fragment:
5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’
3’-GGCAGGAGCTCGTAGCCATGGTAGCTGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’
Single-stranded oligonucleotides to create Phase 86 fragment:
P90a: 5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAG-3’
P90b: 5’-GTTTCTGGCCGACCTTATAACCATGGCATG-3’
P90c: 5’-CATGCCATGGTTATAAGGTCGGCCAGAAACCTTTCTAATGCAAGC-3’
P90d: 5’-GTATAGTCGATGGTACCGATGCTCGAGCACGG-3’

Figure 45. pBLP plasmid inserts.
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Gel Mobility Assay. Two 129 bp DNA fragments, containing the TFO-target sequence,
were amplified by PCR from pBend using primers C1 and C2 to generate the centered
TFO target fragment or E1 and E2 to generate the end-located TFO target fragment. The
fragment was purified by 13% denaturing PAGE followed by extraction from the gel.
The purified centered and end-located TFO target fragments (2 pmol) were incubated
with TFOs (2pmol) in 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2 and 10% sucrose at
37°C for 16h. The TFO-target complexes were analyzed by 8% nondenaturing PAGE
(29:1 cross-linking) containing 10 mM MgCl2. The gel was run in 89 mM Tris borate
and 10 mM MgCl2 buffer (TBM) for 4 h at 10 V/cm and stained with SYBR GOLD
(Molecular Probes) for 45 min. The gel was imaged on a Kodak Digital Science Image
Station.

Gene Expression Analysis. The plasmids pBLP77, pBLP80, pBLP83, and pBLP86
were linearized with NdeI. The linearized plasmids (2.7 nM ) were incubated with excess
TFOs (0.27 μM) in 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2 and 10% sucrose at 37°C
for 16 h. Transcription and translation of the plasmid-TFO complexes was performed
with the EcoPro T7 System (Novagen) and incubation for 1 h at 37°C. A sample of the
expressed luciferase protein (10 μl) was removed and β-galactosidase (200 ng) was
added to each sample as a standard. SDS-PAGE loading buffer was added to each
sample and the samples were then denatured in a thermocycler by incubation at 90°C for
10 min. If the sample was not blue after the addition of the SDS-PAGE loading buffer, 1
μL increments of 1 M Tris (pH 9.5) were added until a blue color was attained. The
samples were run by SDS-PAGE on 10% Tris-HCl Ready Gels (Bio-Rad Laboratories) in
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a 25 mM Tris, 250 mM glycine and 0.1% SDS buffer at 33V/cm for 40 min. The
proteins were transferred from the gel to PVDF membranes in 25 mM Tris, 190 mM
glycine, 20% methanol and 0.1% SDS at 100 V for 1h. The membranes were blocked in
PBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4•7H2O, 1.4 mM KH2PO4)
containing 10% nonfat milk at 4°C with rocking for 16 h and then washed in a wash
buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA and 0.1% Tween-20). The PVDF
membranes were blotted with rabbit-derived anti-β-galactosidase-HRP conjugated
antibodies (1:5000 from a 10 mg/mL stock) and goat-derived anti-luciferas-HRP
conjugated antibodies (1:2000 for a 10 mg/mL stock) in a blotting buffer (100 mM NaCl,
10 mM Tris, 1 mM EDTA, 0.1% Tween-20 and 1% nonfat milk) at 4°C with rocking for
2 h. The membranes were then washed with the wash buffer and treated with an ECL
Western blotting kit (Amersham Biosciences) for 1 min. The membranes were scanned
on a Kodak Digital Science Image Station with a 30 min exposure without UV light or a
filter. The image was analyzed with Kodak 1D Image Analysis software.

V.B. Project 2: A Sequence Selective Push Bender

Synthesis

2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic

acid (3-dimethylamino-propyl)-amide (1).

2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic

acid

ethyl ester (4). N-methylpyrrole-2-carboxylic acid (0.5 g; 4 mmol) and ethyl-2-amino-4phenyl-5-thiazole carboxylate (1 g; 4 mmol) were dissolved, by stirring, into DMF (20
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mL). EDCI (3 g; 16 mmol) and DMAP (2.44 g; 20 mmol) were added and the reaction
mixture was stirred overnight at room temperature. Ethyl acetate (200 mL) was added to
the reaction mixture and the reaction mixture was then washed with 10% aqueous
hydrochloric acid (3 x 200 mL) and saturated aqueous sodium bicarbonate (3 x 200 mL).
The organic layer was collected, dried with magnesium sulfate and was rotavapped to
dryness.

The resulting product was dried overnight under reduced pressure in the

presence of P2O5. Yield 61.6% (0.875 g; 2.46 mmol).

1

H NMR 300 MHz (DMSO-d6)

1.19-1.24 (3H, t, J = 6.6 Hz), 3.93 (3H, s), 4.15-4.22 (2H, q, J = 7.1 Hz), 6.15 (1H, s),
7.05 (1H, s), 7.18 (1H, s), 7.43 (2H, s), 7.71 (2H, s),12.62 (1H, s).

2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic
(5).

acid

2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid

ethyl ester, 4 (0.3123 g; 0.879 mmol) was dissolved in a solution containing 1N lithium
hydroxide (21.66 mL) and methanol (29.06 mL). The reaction mixture was heated to
60°C for 2.5 hours. The reaction mixture was evaporated to half the original volume and
ethyl acetate (75 mL) was added. The aqueous layer was removed and acidified with
concentrated hydrochloric acid until the pH reached 3. The acidic solution was then
extracted with ethyl acetate (4 x 75 mL). The organic layers were collected, dried with
magnesium sulfate and filtered. The filtrate was rotavapped to dryness. The resulting
product was dried overnight under reduced pressure in the presence of P2O5. Yield
74.8% (0.2034 g; 0.657 mmol). 1H NMR 300 MHz (DMSO-d6) 3.93 (3H, s), 6.14 (1H,
s), 6.71 (1H, s), 6.94 (1H, s), 7.17 (1H, s), 7.36-7.42 (2H, t, J = 8.79 Hz), 7.72-7.73 (2H,
d, J = 3.93 Hz), 11.70 (1H, s), 12.53 (1H, s).
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2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid (3dimethylamino-propyl)-amide (1).

2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-

phenyl-thiazole-5-carboxylic acid, 5 (0.03 g; 0.916 mmol) was dissolved in DMF (4 mL).
HBTU (0.086 g; 0.366 mmol) and NMM (0.037 g; 0.366 mmol) were added to the
reaction and the reaction mixture was stirred at room temperaturefor 2 hrs.

3-

(dimethylamino) propylamine (0.028 g; 0.275 mmol) was then added and the reaction
mixture was stirred overnight at room temperature. Ethyl acetate (15 mL) was added to
the reaction mixture and the reaction mixture was washed with water (3 x 15 mL). The
organic layer was collected, dried with magnesium sulfate and filtered. The filtrate was
rotavapped to dryness and purified using silica gel column chromatography using 5:1:0.2
ethyl acetate:methanol:triethylamine. Yield 51.3%

(0.019 g; 0.047 mmol).

1

H NMR

300 MHz (DMSO-d6) 1.65-1.72 (2H, quintet, J = 5.13 Hz), 2.42 (6H, s), 2.49 (1H, s),
2.58-2.62 (2H, t, J = 6.86 Hz), 3.19-3.21 (2H, t, J = 5.31 Hz), 3.82 (3H, s), 6.14 (1H, s),
7.15 (1H, s), 7.41-7.43 (2H, t, J = 6.81 Hz), 7.70-7.72 (2H, d, J = 7.06 Hz), 8.20 (1H, s).
Anal. Calc for C21H25N5O2S.DMF: C 59.61; H 6.46; O 9.93 Found: C 59.11; H 6.02; O
9.33.

Synthesis {5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]1-methyl-1H-pyrrol-3-yl}-carbamic acid tert-butyl ester (2).

2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenylthiazole-5-carboxylic acid ethyl ester (6). 4-tert-Butoxycarbonylamino-1-methyl-1Hpyrrole-2-carboxylic acid (0.96 g; 4 mmol) from Sigma-Aldrich (St. Louis, MO) and
ethyl-2-amino-4-phenyl-5-thiazole carboxylate (1 g; 4 mmol) were dissolved, by stirring,
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into DMF (20 mL). EDCI (3 g; 16 mmol) and DMAP (2.44 g; 20 mmol) were added to
the mixture and the reaction was stirred overnight at room temperature. Ethyl acetate
(200 mL) was then added and the organc layer was then washed with 10% aqueous
hydrochloric acid (3 x 200 mL) and saturated aqueous sodium bicarbonate (3 x 200 mL).
The organic layer was collected, dried with magnesium sulfate and filtered. The filtrate
was rotavapped to dryness.

Yield 51.8% (0.982 g; 2.09 mmol).

1

H NMR 300 MHz

(DMSO-d6) 1.19-1.24 (3H, t, J = 7.07 Hz), 1.45 (9H, s), 3.87 (3H, s), 4.15-4.22 (2H, q, J
= 6.72 Hz), 7.17 (1H, s), 7.25 (1H, s), 7.31 (1H, s), 7.40-7.45 (2H, t, J = 7.53 Hz), 7.717.73 (2H, d, J = 7.08 Hz), 12.67 (1H, s).

2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenylthiazole-5-carboxylic acid (7). 2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid ethyl ester, 6 (0.9824 g; 2.09
mmol) was dissolved into a solution containing 1N lithium hydroxide (51.47 mL) and
methanol (69.04 mL). The reaction mixture was heated to 60°C for 3 hours, cooled and
evaporated to half the original volume. The resulting solution was extracted with ethyl
acetate (175 mL) and the aqueous layer of the extraction was acidified with concentrated
hydrochloric acid to pH 3. The acidic aqueous layer was then extracted with ethyl acetate
(4 x 175 mL), the organic layers were collected, dried with magnesium sulfate and
filtered. The filtrate was rotavapped to dryness. Yield 71.9% (0.665 g; 1.51 mmol). 1H
NMR 300 MHz (DMSO-d6) 1.45 (9H, s), 3.87 (3H, s), 7.04 (1H, s), 7.16 (1H, s), 7.35
(2H, s), 7.71-7.73 (2H, d, J = 4.14 Hz), 9.05 (1H, s), 9.21 (1H, s), 12.57 (1H, s).
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{5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]-1methyl-1H-pyrrol-3-yl}-carbamic

acid

tert-butyl

ester

2-[(4-tert-

(2).

butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5carboxylic acid, 7 (0.03 g; 0.068 mmol) was dissolved in DMF (4 mL). HBTU (0.064 g;
0.272 mmol) and NMM (0.028 g; 0.272 mmol) were added to the reaction. The reaction
mixture stirred at room temperature for 2 hrs followed by the addition of 3(dimethylamino) propylamine (0.021 g; 0.203 mmol). The reaction mixture was stirred
overnight at room temperature followed by addition of ethyl acetate (15 mL) to the
reaction mixture. The organic layer was washed with water (3 x 15 mL), collected, dried
with magnesium sulfate and filtered. The filtrate was rotavapped to dryness and the
resulting product was purified by silica gel column chromatography using 5:1:0.2 ethyl
acetate:methanol:triethylamine. Yield 60.3% (0.022 g; 0.041 mmol).

1

H NMR 300

MHz (DMSO-d6) 1.46 (9H, s), 1.53-1.57 (2H, t, J = 6.21 Hz), 2.08 (6H, s), 2.13-2.19
(2H, quintet, J = 4.65 Hz), 3.17-3.19 (2H, t, J = 5.62 Hz), 3.87 (3H, s), 7.14 (1H, s), 7.20
(1H, s), 7.40-7.42 (2H, d, J = 7.22 Hz), 7.69-7.72 (2H, d, J = 6.69 Hz), 8.09 (1H, s), 9.18
(1H, s). Anal. Calc for C26H34N6O4S.DMF: C 59.30; H 6.51; O 12.15 Found: C 58.99; H
6.33; O 12.47.

Synthesis

of

2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-

thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide (3).

2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5carboxylic acid (3-dimethylamino-propyl)-amide (3).

{5-[5-(3-Dimethylamino-

propylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]-1-methyl-1H-pyrrol-3-yl}-carbamic
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acid tert-butyl ester, 2 (0.070 g; 0.133 mmol) was dissolved in dichloromethane (5 mL).
Trifluoroacetic acid (0.3 mL) and benzenethiol (0.1 mL) were added and the reaction
mixture was stirred at room temperature for 1 hour. The reaction was rotavapped to
dryness and the residue was washed with diethyl ether (3 x 15 mL) to remove non-polar
impurities. The residue was dissolved in ethanol (10 mL) and ethyl formate (20 mL) was
added. The reaction was heated to reflux for 48 hours, cooled and evaporated to dryness.
The resulting residue was then purified by silica gel column chromatography using
5:1:0.2 ethyl acetate:methanol:triethylamine. Yield 73.4% (0.044 g; 0.098 mmol).

1

H

NMR 300 MHz (DMSO-d6) 1.72-1.81 (2H, quintet, J = 5.43 Hz), 2.64 (6H, s), 2.84-2.90
(2H, t, J = 8.28 Hz), 3.07-3.09 (2H, t, J = 6.87 Hz), 3.90 (3H, s), 7.33 (1H, s), 7.41-7.45
(2H, d, J = 9.21 Hz), 7.70-7.72 (2H, d, J = 6.33 Hz), 8.14 (1H, s), 8.24 (1H, s), 10.17
(1H, s). Anal. Calc for C22H26N6O3S.CH3CH2OH: C 57.58; H 6.44; O 12.78 Found: C
58.01; H 6.12; O 12.50.

Ethidium bromide displacement assay. This assay was performed on a Perkins Elmer
L555 Fluorimeter equipped with FL WinLab software. The assay was conducted as
follows. Ethidium bromide (4.4 μM final concentration) was added to a quartz cuvette
containing Tris buffer (0.1 M Tris, 0.1 M NaCl, pH 8). The fluorescence was measured
(ex. 545 nm, em. 595 nm). The DNA target of interest was added (8.8 μM in DNA base
pairs final concentration) and the fluorescence was again measured. Compounds 1, 2 and

3 were then titrated into the cuvette, measuring the fluorescence 5 min after every
addition. Each compound was titrated until the relative fluorescence had decreased to
less than 50%.
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FRET analysis. Two 19-bp DNA targets were diluted to 0.5 μM in 10 mM sodium
phosphate buffer (pH 7). One duplex contained a 5’-terminal fluorescein, while the other
duplex contained both a 5’-terminal fluorescein and a terminal tetramethylrhodamine on
the other strand. The emission spectrum for each of these duplexes was analyzed in both
the absence and presence of compounds 1, 2 and 3. The samples were analyzed on a
PerkinElmer Instruments LS55 Luminescence Spectrometer with corresponding FL
WinLab software. The excitation and emission slits of the machine were set to 3 nm and
10 nm, respectively. The samples were excited at 495 nm and the emissions were
scanned from 500 nm to 700 nm. Data analysis utilized the integrated area under of the
various spectrums from 510 nm to 530 nm as calculated with the FL WinLab software.
The emission spectrums for 1 ml of each DNA target, at 0.5 μM in a quartz cuvette, were
first scanned without any of the synthesized compounds present. The samples were then
scanned after the addition of compounds 1, 2 and 3, in excess at 2.0 μM, and a 15 minute
incubation period at room temperature.
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VI. 1H-NMR Spectra

Figure 46. 1H-NMR Spectrum of compound 1 in DMSO-d6.

104

Figure 47. 1H-NMR Spectrum of compound 2 in DMSO-d6.
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Figure 48. 1H-NMR Spectrum of compound 3 in DMSO-d6.

106

Figure 49. 1H-NMR Spectrum of compound 4 in DMSO-d6.
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Figure 50. 1H-NMR Spectrum of compound 5 in DMSO-d6.
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Figure 51. 1H-NMR Spectrum of compound 6 in DMSO-d6.
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Figure 52. 1H-NMR Spectrum of compound 7 in DMSO-d6.
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VII. Appendix A: Statistical Difference in Percent Change in Luciferase Expression
Table V. Significant Difference between the Percent Change in Luciferase Expression
Levels Caused by the Various Tethered-TFOs for Individual pBLP Plasmids at a 95%
Confidence Level

pBLP77

pBLP80

pBLP83

pBLP86

none
STFO
LTFO
bSTFO
bLTFO
none
STFO
LTFO
bSTFO
bLTFO
none
STFO
LTFO
bSTFO
bLTFO
none
STFO
LTFO
bSTFO
bLTFO

none
Y
Y
N
N
Y
N
N
N
Y
Y
Y
N
Y
N
N
N

STFO
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

LTFO
Y
Y
N
N
N
Y
N
N
Y
Y
N
N
N
Y
N
N

bSTFO
N
Y
N
N
N
Y
N
N
Y
Y
N
N
N
Y
N
N

bLTFO
N
Y
N
N
N
Y
N
N
N
Y
N
N
N
Y
N
N
-

Y = Yes; significant difference in the change in expression levels with 95% confidence
N = No; there was no significant difference
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Table VI. Significant Difference between the Percent Change in Luciferase Expression
Levels Between the pBLP Plasmids for the Various Tethered-TFOs at a 95% Confidence
Level
STFO

LTFO

bSTFO

bLTFO

pBLP77
pBLP80
pBLP83
pBLP86
pBLP77
pBLP80
pBLP83
pBLP86
pBLP77
pBLP80
pBLP83
pBLP86
pBLP77
pBLP80
pBLP83
pBLP86

pBLP77
Y
Y
N
N
Y
N
N
Y
N
N
N
N

pBLP80
Y
Y
Y
N
N
N
N
N
N
N
N
N

pBLP83
Y
Y
Y
Y
N
N
Y
N
N
N
N
N

pBLP86
N
Y
Y
N
N
N
N
N
N
N
N
N
-

Y = Yes; significant difference in the change in expression levels with 95% confidence
N = No; there was no significant difference
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VIII. Appendix B: Reaction Mechanisms
VIII.A. Amide bond formation of Compounds 4 and 6 in Schemes I and II
Condensation of N-methylpyrrole-2-carboxylic acid (where R was a proton, H) or 4-tertbutoxycarbonylamino-1-methyl-1H-pyrrole-2-carboxylic acid (where R was –NHBoc)
and ethyl-2-amino-4-phenyl-5-thiazole carboxylate with EDCI and DMAP, to form 4 or
6, schemes I and II.
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VIII.B. C-terminal ester hydrolysis to form 5 and 7 in Schemes I and II
Hydrolysis of C-terminal esters of compounds 4 and 6 with 1N LiOH to generate free
carboxylic acid, compounds 5 and 7, schemes I and II.
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VIII.C. Addition of C-terminal tail to form 1 and 2 in Schemes I and II
HBTU and NMM coupling conditions were used to form an amide bond between the Cterminal carboxylic acids of compounds 5 and 7 and the primary amine of 3(dimethylamino)propylamine to form the final products, 1 and 2, schemes and II.
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VIII.D. Scheme III reactions
VIII.D.1. Deprotection of N-terminal Boc group of compound 2
Deprotection of Boc group of compound 2 with TFA and benzenethiol, as a carbocation
scavenger, to yield a free amine at the N-terminus of the molecule, scheme III.
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VIII.D.2. Ethyl formate reaction to form N-terminal formamide of 3
The N-terminal free amine generated by Boc group deprotection was immediately reacted
with ethyl formate to generate the formamide, compound 3, scheme III.
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